


Stocks/Country/United States Index - Markets Index
























Bulletin






Investor Alert



















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Location: United States



Name
Exchange
Sector




01 Communique Laboratory Inc. (OCQLF)
OOTC
Software


1347 Property Insurance Holdings Inc. (PIH)
XNAS
Non-Life Insurance


1-800-FLOWERS.COM Inc. Cl A (FLWS)
XNAS
Specialty Retail


1pm Industries Inc. (OPMZ)
OOTC
Food Products


1st Capital Bank (CA) (FISB)
OOTC
Banking


1st Constitution Bancorp (FCCY)
XNAS
Banking


1st NRG Corp. (FNRC)
OOTC
Oil Extraction


1st Source Corp. (SRCE)
XNAS
Banking


2050 Motors Inc. (ETFM)
OOTC
Automobiles


21st Century Fox Inc. Cl A (FOXA)
XNAS
Broadcasting


21st Century Fox Inc. Cl B (FOX)
XNAS
Broadcasting


21Vianet Group Inc. ADR (VNET)
XNAS
Internet/Online


22nd Century Group Inc. (XXII)
XASE
Biotechnology


24/7 Kid Doc Inc. (TVMD)
OOTC
Healthcare Provision


2U Inc. (TWOU)
XNAS
Software


2xLeveraged Long E-TRACS Linked to Wells Fargo Business Development Co. Index 052441 (BDCL)
ARCX
Major International Banks


2xLeveraged Long ETRACS Wells Fargo Business Development (LBDC)
ARCX
Major International Banks


3D Eye Solutions Inc. (TDEY)
OOTC
Motion Picture/Sound Recording


3D Pioneer Systems Inc. (DPSM)
OOTC
Software


3D Systems Corp. (DDD)
XNYS
Computers/Consumer Electronics


3DIcon Corp. (TDCP)
OOTC
Software


3Dshopping.com (THDS)
OOTC
Mixed Retailing


3DX Industries Inc. (DDDX)
OOTC
Computers/Consumer Electronics


3i Group PLC ADR (TGOPY)
OOTC
Finance Companies


3M Co. (MMM)
XNYS
Diversified Holding Companies


3Pea International Inc. (TPNL)
XOTC
Accounting


3Power Energy Group Inc. (PSPW)
OOTC
Renewable Energy Generation


3TL Technologies Corp. (TTMZF)
OOTC
Advertising/Marketing/Public Relations


420 Property Management Inc. (FTPM)
OOTC
Real Estate Agents/Brokers


4Cable TV International Inc. (CATV)
OOTC
Diversified Business Services


4Licensing Corp. (FOURQ)
OOTC
Diversified Business Services


500.com Ltd. ADR (WBAI)
XNYS
Gambling Industries


51job Inc. ADR (JOBS)
XNAS
Employment/Training Services


58.com Inc. ADR (WUBA)
XNYS
Consumer Services


5Barz International Inc. (BARZ)
OOTC
Networking


5N Plus Inc. (FPLSF)
OOTC
Commodity Chemicals


6D Global Technologies Inc. (SIXD)
OOTC
Computer Services


808 Renewable Energy Corp. (RNWR)
OOTC
Multiutilities


88 Energy Ltd. ADR (TNGRY)
OOTC
Oil Extraction


888 Holdings PLC (EIHDF)
OOTC
Gambling Industries


8Point3 Energy Partners LP (CAFD)
XNAS
Renewable Energy Generation


8X8 Inc. (EGHT)
XNAS
Wired Telecommunications Services


A Clean Slate Inc. (DRWN)
OOTC
Diversified Business Services


A&W Revenue Royalties Income Fund (AWRRF)
OOTC
Restaurants


A. H. Belo Corp. Series A (AHC)
XNYS
Publishing


A. Schulman Inc. (SHLM)
XNAS
Commodity Chemicals


A. Schulman Inc. 6% Pfd. (SLMNP)
OOTC
Commodity Chemicals


A.D. Makepeace Co. (MAKE)
OOTC
Farming


A.M. Castle & Co. (CAS)
XNYS
Wholesalers


A.O. Smith Corp. (AOS)
XNYS
Building Materials/Products


A.P. Moeller-Maersk A/S ADR (AMKBY)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series A (AMKAF)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series B (AMKBF)
OOTC
Water Transport/Shipping


A.S. Roma S.p.A. (ASRAF)
OOTC
Recreational Services


A-1 Group Inc. (AWON)
OOTC
Tobacco


A10 Networks Inc. (ATEN)
XNYS
Computer Services


a2 Milk Co. Ltd. (ACOPF)
OOTC
Biotechnology


AAC Holdings Inc. (AAC)
XNYS
Healthcare Provision


AAC Technologies Holdings Inc. (AACAF)
OOTC
Industrial Electronics


AAC Technologies Holdings Inc. ADR (AACAY)
OOTC
Industrial Electronics


AAON Inc. (AAON)
XNAS
Building Materials/Products


AAP Inc. (AAPJ)
OOTC
Food Products


AAR Corp. (AIR)
XNYS
Aerospace Products/Parts


Aaron's Inc. (AAN)
XNYS
Consumer Services


AB Science S.A. (ABSCF)
OOTC
Pharmaceuticals


AB Svensk Exportkredit ELEMENTS linked to MLCX Biofuels Index Total Return (FUE)
ARCX
Finance Companies


AB Svensk Exportkredit ELEMENTS linked to MLCX Grain Index Total Return (GRU)
ARCX
Finance Companies


AB&T Financial Corp. (ABTO)
OOTC
Banking


Abacus Mining & Exploration Corp. (ABCFF)
OOTC
General Mining


Abakan Inc. (ABKI)
OOTC
Industrial Products


Abattis Bioceuticals Corp. (ATTBF)
OOTC
Biotechnology


Abaxis Inc. (ABAX)
XNAS
Medical Equipment/Supplies


ABB Ltd. (ABLZF)
OOTC
Industrial Machinery


ABB Ltd. ADR (ABB)
XNYS
Industrial Machinery


Abbott Laboratories (ABT)
XNYS
Pharmaceuticals


AbbVie Inc. (ABBV)
XNYS
Biotechnology


Abby Inc. (ABBY)
OOTC
Oil Extraction


Abcam PLC (ABCZF)
OOTC
Biotechnology


Abcam PLC ADR (ABCZY)
OOTC
Biotechnology


ABCO Energy Inc. (ABCE)
OOTC
Industrial Machinery


Abcourt Mines Inc. (ABMBF)
OOTC
General Mining


Aben Resources Ltd. (ABNAF)
OOTC
General Mining


Abengoa S.A. B (AGOAF)
OOTC
Construction


Abeona Therapeutics Inc. (ABEO)
XNAS
Biotechnology


Abeona Therapeutics Inc. Wt (ABEOW)
XNAS



Abercrombie & Fitch Co. (ANF)
XNYS
Clothing Retail


Aberdeen Asia-Pacific Income Fund Inc. (FAX)
XASE
Closed-End Funds


Aberdeen Asia-Pacific Income Investment Co. Ltd. (ABAKF)
OOTC
Closed-End Funds


Aberdeen Asset Management PLC (ABDNF)
OOTC
Investment Advisors


Aberdeen Asset Management PLC ADR (ABDNY)
OOTC
Investment Advisors


Aberdeen Australia Equity Fund Inc. (IAF)
XASE
Closed-End Funds


Aberdeen Chile Fund Inc. (CH)
XASE
Closed-End Funds


Aberdeen Emerging Markets Smaller Company Opportunities Fund Inc. (ABE)
XASE
Closed-End Funds


Aberdeen Global Income Fund Inc. (FCO)
XASE
Closed-End Funds


Aberdeen Greater China Fund Inc. (GCH)
XNYS
Closed-End Funds


Aberdeen Indonesia Fund Inc. (IF)
XASE
Closed-End Funds


Aberdeen International Inc. (AABVF)
OOTC
General Mining


Aberdeen Israel Fund Inc. (ISL)
XASE
Closed-End Funds


Aberdeen Japan Equity Fund Inc. (JEQ)
XNYS
Closed-End Funds


Aberdeen Latin America Equity Fund Inc. (LAQ)
XASE
Closed-End Funds


Aberdeen Singapore Fund Inc. (SGF)
XNYS
Closed-End Funds


Abertis Infraestructuras S.A. ADR (ABRTY)
OOTC
Transportation Services


Ability Inc. (ABIL)
XNAS
Precision Products


Ability Inc. Wt (ABIWF)
OOTC



Abiomed Inc. (ABMD)
XNAS
Medical Equipment/Supplies


Abitibi Royalties Inc. (ATBYF)
OOTC
General Mining


Able Energy Inc. (ABLE)
OOTC
Gas Utilities


Ablynx N.V. (ABLYF)
OOTC
Biotechnology


ABM Industries Inc. (ABM)
XNYS
Diversified Business Services


Abraxas Petroleum Corp. (AXAS)
XNAS
Oil Extraction


Absecon Bancorp (ASCN)
OOTC
Banking


Absolute Health & Fitness Inc. (AHFI)
OOTC
Recreational Services


Absolute Software Corp. (ALSWF)
OOTC
Software


ABT Holdings Inc. (ABOT)
OOTC
Precious Metals


Abtech Holdings Inc. (ABHD)
OOTC
Industrial Machinery


ABV Consulting Inc. (ABVN)
OOTC
Advertising/Marketing/Public Relations


AC Immune S.A. (ACIU)
XNAS
Biotechnology


Acacia Communications Inc. (ACIA)
XNAS
Networking


Acacia Diversified Holdings Inc. (ACCA)
OOTC
Specialty Retail


Acacia Mining PLC (ABGLF)
OOTC
Gold


Acacia Research Corp. - Acacia Technologies (ACTG)
XNAS
Diversified Business Services


Acadia Healthcare Co. Inc. (ACHC)
XNAS
Healthcare Provision


ACADIA Pharmaceuticals Inc. (ACAD)
XNAS
Biotechnology


Acadia Realty Trust (AKR)
XNYS



Acadian Timber Corp. (ACAZF)
OOTC
Forestry & Wood Products


Acasti Pharma Inc. (ACST)
XNAS
Pharmaceuticals


Accelera Innovations Inc. (ACNV)
OOTC
Healthcare Provision


Accelerate Diagnostics Inc. (AXDX)
XNAS
Biotechnology


Accelerize Inc. (ACLZ)
XOTC
Life Insurance


Acceleron Pharma Inc. (XLRN)
XNAS
Biotechnology


Accenture PLC Cl A (ACN)
XNYS
Diversified Business Services


Access National Corp. (ANCX)
XNAS
Banking


Access Power Inc. (ACCR)
OOTC
Wired Telecommunications Services


Access Worldwide Communications Inc. (AWWC)
OOTC
Advertising/Marketing/Public Relations


Acciona S.A. (ACXIF)
OOTC
Construction


ACCO Brands Corp. (ACCO)
XNYS
Nondurable Household Products


Accor S.A. (ACRFF)
OOTC
Hotels


Accor S.A. ADR (ACCYY)
OOTC
Hotels


Accordia Golf Co. Ltd. (ACGFF)
OOTC
Recreational Services


Accredited Mortgage Loan REIT Trust 9.75% Perp. Cum. Pfd. Series A (AHHAP)
OOTC
Mortgages


Accretive Health Inc. (ACHI)
OOTC
Healthcare Provision


Accuray Inc. (ARAY)
XNAS
Medical Equipment/Supplies


Accuride Corp. (ACW)
XNYS
Auto & Commercial Vehicle Parts


AcelRx Pharmaceuticals Inc. (ACRX)
XNAS
Pharmaceuticals


Acer Inc. GDR Reg S (ACEYY)
OOTC
Computers/Consumer Electronics


Acerus Pharmaceuticals Corp. (TRLPF)
OOTC
Biotechnology


Aceto Corp. (ACET)
XNAS
Specialty Chemicals


Achaogen Inc. (AKAO)
XNAS
Biotechnology


Achillion Pharmaceuticals Inc. (ACHN)
XNAS
Biotechnology


ACI Worldwide Inc. (ACIW)
XNAS
Software



«1234567891011-2021-3031-4041-5051-6061-7071-8081-9091-94»










Log In




11:29 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


















































VICL Stock Price - Vical Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,830.31


33.76


0.15%











S&P 500

2,472.10


-3.32


-0.13%











Nasdaq

6,374.68


-7.51


-0.12%











GlobalDow

2,848.22


-2.86


-0.10%











Gold

1,275.60


9.10


0.72%











Oil

49.79


0.75


1.53%

















S&P 500 Movers(%)



ALGN 
10.0




MHK 
4.3




COL 
4.3




LYB 
3.9






FLS
-10.9




MO
-9.5




SBUX
-9.2




GT
-8.4














Latest NewsAll Times Eastern








9:15p

Updated
Wall Street isn’t ready for a 1,100-point tumble in the Dow industrials



7:38p

Barron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News



7:28p

A Wild Week in Washington 



6:32p

Updated
The dark side of cruises



6:31p

 Trump to Police: 'Don't Be Too Nice'



6:31p

Updated
The highest paid athletes in the world, in one chart



6:31p

Updated
O.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family



6:30p

Updated
Here are 10 co-workers you should avoid like the plague — especially in meetings



6:29p

Updated
Top 10 most annoying people you may want to unfriend on Facebook 



6:28p

Updated
This is one person you should never unfriend on Facebook...












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


VICL


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors
Nasdaq

 



VICL
U.S.: Nasdaq


Join TD Ameritrade

Find a Broker


Vical Inc.

Watchlist 
CreateVICLAlert



  


Closed

Last Updated: Jul 28, 2017 3:59 p.m. EDT
Delayed quote



$
2.58



-0.04
-1.53%






Previous Close




$2.6200





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




60.68% vs Avg.




                Volume:               
                
                    41.6K
                


                65 Day Avg. - 68.5K
            





Open: 2.5936
Close: 2.58



2.5800
Day Low/High
2.6900





Day Range



2.0500
52 Week Low/High
4.5000


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$2.5936



Day Range
2.5800 - 2.6900



52 Week Range
2.0500 - 4.5000



Market Cap
$29.07M



Shares Outstanding
11.1M



Public Float
8.34M



Beta
0.93



Rev. per Employee
$179.89K



P/E Ratio
n/a



EPS
$-0.88



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
115.91K
07/14/17


% of Float Shorted
1.39%



Average Volume
68.49K




 


Performance




5 Day


-3.01%







1 Month


-3.01%







3 Month


9.32%







YTD


12.17%







1 Year


-37.83%









  

 
 


Recent News



MarketWatch
Other Dow Jones










J.C. Penney and more of the year's most profitable shorts


Dec. 9, 2013 at 3:23 p.m. ET










Monday’s movers: BlackBerry, Apple, Tesla

Aug. 12, 2013 at 4:30 p.m. ET
by Maria LaMagna










Stock futures knocked by Japan data, taper fears

Aug. 12, 2013 at 9:19 a.m. ET
by William L. Watts









Vical shares plunge 62% premarket after drug trial


Aug. 12, 2013 at 7:37 a.m. ET
by Saumya Vaishampayan









Vical off nearly 60% on drug disappointment


Aug. 12, 2013 at 7:30 a.m. ET
by Barbara Kollmeyer









Stocks to Watch Friday: Analogic, Werner


Sep. 13, 2012 at 4:36 p.m. ET
by David B. Wilkerson










Thursday’s biggest gaining and declining stocks

Sep. 13, 2012 at 3:39 p.m. ET
by MarketWatch









Friday’s biggest gaining and declining stocks


Jan. 6, 2012 at 4:44 p.m. ET
by Kate Gibson









Vical  slides 12% on stock offering


Jan. 6, 2012 at 11:56 a.m. ET
by Val Brickates Kennedy









Friday’s biggest gaining and declining stocks


Jul. 15, 2011 at 3:49 p.m. ET
by Kate Gibson









Vical jumps 7% on vaccine deal


Jul. 15, 2011 at 12:06 p.m. ET
by Val Brickates Kennedy










Google rallies after hours following results

Jul. 14, 2011 at 5:57 p.m. ET
by Carla Mozee









Vical, BioSante boost drug sector


Feb. 14, 2011 at 1:44 p.m. ET
by Val Brickates Kennedy









Friday’s biggest gaining and declining stocks


Sep. 24, 2010 at 2:44 p.m. ET
by MarketWatch









Wednesday’s biggest gaining and declining stocks


Sep. 22, 2010 at 7:37 p.m. ET
by MarketWatch









Biogen Idec and Vical shares fall


Sep. 22, 2010 at 11:42 a.m. ET
by Val Brickates Kennedy









Vical shares crushed by failed drug trial


Sep. 22, 2010 at 10:08 a.m. ET
by Val Brickates Kennedy









Thursday's biggest gaining and declining stocks


Feb. 11, 2010 at 4:46 p.m. ET
by MarketWatch









Monday's biggest gaining and declining stocks


Dec. 28, 2009 at 4:56 p.m. ET
by MarketWatch









Vical, Compugen lead drug stocks north


Dec. 28, 2009 at 12:59 p.m. ET
by Val Brickates Kennedy














Stocks to Watch: Darden, 3M, Sonic

Jun. 23, 2015 at 9:37 a.m. ET
on The Wall Street Journal









Vical’s Herpes Vaccine Didn’t Meet Primary Endpoint


Jun. 22, 2015 at 5:05 p.m. ET
on The Wall Street Journal









Stocks Finish Flat


Aug. 12, 2013 at 4:20 p.m. ET
on The Wall Street Journal









Stocks to Watch: BlackBerry, Vical, Steinway


Aug. 12, 2013 at 9:51 a.m. ET
on The Wall Street Journal










Stocks to Watch: Apple, K12, Pall Corp

Sep. 13, 2012 at 9:08 a.m. ET
on The Wall Street Journal









Satyam Computer Services, Vical: Biggest Price Decliners (SAY, VICL)


Sep. 24, 2010 at 12:51 p.m. ET
on The Wall Street Journal









iStar Financial, Vical: Biggest Price Decliners (SFI, VICL)


Sep. 22, 2010 at 4:56 p.m. ET
on The Wall Street Journal









iStar Financial, Vical: Biggest Price Decliners (SFI, VICL)


Sep. 22, 2010 at 12:56 p.m. ET
on The Wall Street Journal









BioSante Falls, Schnitzer Sinks


Jun. 30, 2009 at 8:46 p.m. ET
on The Wall Street Journal









New Tack With Bird-Flu Vaccine


Jul. 17, 2008 at 12:01 a.m. ET
on The Wall Street Journal









Harvest Natural Resources, Vical: Biggest Price Gainers (HNR, VICL)


Jun. 18, 2007 at 4:42 p.m. ET
on The Wall Street Journal









Shares of Some Banks Show Weakness


Oct. 21, 2006 at 12:01 a.m. ET
on The Wall Street Journal









Blue Dolphin and EpiCept Jump


Apr. 1, 2006 at 12:01 a.m. ET
on The Wall Street Journal









Skyworks, Kopin, Zoran Decline


Oct. 12, 2005 at 12:01 a.m. ET
on The Wall Street Journal









NIH to Launch Study of AIDS Vaccine


Oct. 11, 2005 at 8:01 p.m. ET
on The Wall Street Journal









DNA-Based Vaccines May Help Humans


Sep. 23, 2005 at 12:01 a.m. ET
on The Wall Street Journal









Innogenetics Carves Out Niche


Jul. 8, 2004 at 12:01 a.m. ET
on The Wall Street Journal









Input/Output, Superior Energy Rise


Feb. 10, 2004 at 7:25 p.m. ET
on The Wall Street Journal









Standard Pacific, Beazer Tumble


Jul. 15, 2003 at 8:49 p.m. ET
on The Wall Street Journal









Upgrades Boost Small Caps


Jul. 2, 2003 at 9:22 p.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More
Stocks were indicated to open slightly lower on Monday after some of the top momentum and crowded technology companies took it on the chin on Friday. Still, a rotation took place into more stable names and into other sectors as the top market darlings slid. This bull market is now over eight years old and [ ]

Jun. 12, 2017 at 8:17 a.m. ET
on 247WallSt.com





Premarket analyst action - healthcare
Premarket analyst action - healthcare

Jun. 12, 2017 at 8:59 a.m. ET
on Seeking Alpha





10-Q: VICAL INC
10-Q: VICAL INC

May. 15, 2017 at 3:34 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q1 2017 Results - Earnings Call Transcript
Vical's (VICL) CEO Vijay Samant on Q1 2017 Results - Earnings Call Transcript

May. 15, 2017 at 3:14 p.m. ET
on Seeking Alpha





Vical completes enrollment in mid-stage study of HSV-2 vaccine


Apr. 19, 2017 at 6:50 a.m. ET
on Seeking Alpha





Premarket Gainers as of 9:05 am


Apr. 5, 2017 at 9:25 a.m. ET
on Seeking Alpha





Vical inks hep B research deal with AnGes MG; shares ahead 11% premarket


Apr. 5, 2017 at 8:31 a.m. ET
on Seeking Alpha





Vical (VICL) Presents At 29th Annual ROTH Conference


Mar. 16, 2017 at 2:10 p.m. ET
on Seeking Alpha





10-K: VICAL INC


Mar. 10, 2017 at 4:05 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call Transcript


Mar. 10, 2017 at 12:46 a.m. ET
on Seeking Alpha





Is The Big Crash Coming? Why The Market Continues To Run


Mar. 1, 2017 at 2:41 p.m. ET
on Seeking Alpha





Vical: A Risky Net-Net Provides The Potential For A Profitable Swing Trade


Jan. 10, 2017 at 11:25 a.m. ET
on Seeking Alpha





52 Biotechnology Stocks to Sell Now


Nov. 14, 2016 at 9:00 a.m. ET
on InvestorPlace.com





27 Biotechnology Stocks to Sell Now


Nov. 7, 2016 at 8:45 a.m. ET
on InvestorPlace.com





10-Q: VICAL INC


Nov. 4, 2016 at 2:34 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





The Best Net-Net Stocks On Wall-Street Today


Nov. 4, 2016 at 8:51 a.m. ET
on Seeking Alpha





Vical's (VICL) CEO Vijay Samant on Q3 2016 Results - Earnings Call Transcript


Nov. 3, 2016 at 2:34 p.m. ET
on Seeking Alpha





Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study


Sep. 20, 2016 at 4:16 p.m. ET
on Zacks.com





Biotech Forum Daily Digest: FDA Finally Caves On Sarepta. Biotech Rally Continues. Spotlight On Sage Therapeutics


Sep. 19, 2016 at 2:54 p.m. ET
on Seeking Alpha





Hottest Manufacturing Stocks Now – SRPT TANH SORL PTCT


Sep. 19, 2016 at 10:30 a.m. ET
on InvestorPlace.com









Vical to Provide Company Update at the 2017 BIO International Convention
Vical to Provide Company Update at the 2017 BIO International Convention

Jun. 15, 2017 at 4:05 p.m. ET
on GlobeNewswire





Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

Jun. 5, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting

May. 23, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network: Vical Incorporated to Host Earnings Call
Investor Network: Vical Incorporated to Host Earnings Call

May. 15, 2017 at 9:00 a.m. ET
on ACCESSWIRE





Vical Reports First Quarter 2017 Financial Results
Vical Reports First Quarter 2017 Financial Results

May. 15, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017
Investor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017

May. 12, 2017 at 4:09 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results

May. 8, 2017 at 6:30 a.m. ET
on GlobeNewswire





Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day

May. 2, 2017 at 4:36 p.m. ET
on GlobeNewswire





Vical to Host Virtual Research & Development Day on May 2, 2017


Apr. 24, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial


Apr. 19, 2017 at 6:30 a.m. ET
on GlobeNewswire





Vical to Provide Company Update at the 29th Annual ROTH Conference


Mar. 10, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical to Provide Company Update at BIO Asia International Conference


Mar. 9, 2017 at 7:01 a.m. ET
on GlobeNewswire





Vical Reports Fourth Quarter 2016 Financial Results


Mar. 9, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network Invites You to the Vical Fourth Quarter 2016 Earnings Webcast Live on Thursday, March 9, 2017


Mar. 8, 2017 at 4:11 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results


Mar. 2, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Provides Company Update at Biocom's Global Life Science Partnering Conference


Feb. 24, 2017 at 3:00 p.m. ET
on GlobeNewswire





Vical Provides Company Update at BIO CEO and Investor Conference


Feb. 7, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Reports Third Quarter 2016 Financial Results


Nov. 3, 2016 at 6:31 a.m. ET
on GlobeNewswire





Investor Calendar Invites You to the Vical Third Quarter 2016 Earnings Webcast Live on Thursday, November 3, 2016


Nov. 2, 2016 at 4:25 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for Third Quarter 2016 Financial Results


Oct. 27, 2016 at 6:31 a.m. ET
on GlobeNewswire











Vical Inc.


            
            Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. The company's pipeline consists of ASP0113 Therapeutic CMV Vaccine, CyMVectin Prophylactic CMV Vaccine and VL-2397 Antifungal. Vical was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

            
            (See Full Profile)


  




Analyst Ratings



Sell
Under
Hold
Over
Buy

Number of Ratings 2
Full Ratings 





Benzinga's Top Initiations


Jul. 19, 2016 at 9:26 a.m. ET
on Benzinga.com





 


Competitors




Name
Chg %
Market Cap




Celldex Therapeutics Inc.
0.00%
$287.74M


Bristol-Myers Squibb Co.
1.90%
$88.95B


Pfizer Inc.
0.45%
$196.94B


Sanofi ADR
-1.10%
$120.91B


Merck & Co. Inc.
0.66%
$174.2B




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





DVAX

0.00%








S

0.24%








SSTI

-0.08%








MO

-9.49%








TRUE

1.33%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.












VICL Stock Price - Vical Inc. Stock Quote (U.S.: Nasdaq) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,830.31


33.76


0.15%











S&P 500

2,472.10


-3.32


-0.13%











Nasdaq

6,374.68


-7.51


-0.12%











GlobalDow

2,848.22


-2.86


-0.10%











Gold

1,275.60


9.10


0.72%











Oil

49.79


0.75


1.53%

















S&P 500 Movers(%)



ALGN 
10.0




MHK 
4.3




COL 
4.3




LYB 
3.9






FLS
-10.9




MO
-9.5




SBUX
-9.2




GT
-8.4














Latest NewsAll Times Eastern








9:15p

Updated
Wall Street isn’t ready for a 1,100-point tumble in the Dow industrials



7:38p

Barron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News



7:28p

A Wild Week in Washington 



6:32p

Updated
The dark side of cruises



6:31p

 Trump to Police: 'Don't Be Too Nice'



6:31p

Updated
The highest paid athletes in the world, in one chart



6:31p

Updated
O.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family



6:30p

Updated
Here are 10 co-workers you should avoid like the plague — especially in meetings



6:29p

Updated
Top 10 most annoying people you may want to unfriend on Facebook 



6:28p

Updated
This is one person you should never unfriend on Facebook...












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


VICL


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors
Nasdaq

 



VICL
U.S.: Nasdaq


Join TD Ameritrade

Find a Broker


Vical Inc.

Watchlist 
CreateVICLAlert



  


Closed

Last Updated: Jul 28, 2017 3:59 p.m. EDT
Delayed quote



$
2.58



-0.04
-1.53%






Previous Close




$2.6200





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




60.68% vs Avg.




                Volume:               
                
                    41.6K
                


                65 Day Avg. - 68.5K
            





Open: 2.5936
Close: 2.58



2.5800
Day Low/High
2.6900





Day Range



2.0500
52 Week Low/High
4.5000


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$2.5936



Day Range
2.5800 - 2.6900



52 Week Range
2.0500 - 4.5000



Market Cap
$29.07M



Shares Outstanding
11.1M



Public Float
8.34M



Beta
0.93



Rev. per Employee
$179.89K



P/E Ratio
n/a



EPS
$-0.88



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
115.91K
07/14/17


% of Float Shorted
1.39%



Average Volume
68.49K




 


Performance




5 Day


-3.01%







1 Month


-3.01%







3 Month


9.32%







YTD


12.17%







1 Year


-37.83%









  

 
 


Recent News



MarketWatch
Other Dow Jones










J.C. Penney and more of the year's most profitable shorts


Dec. 9, 2013 at 3:23 p.m. ET










Monday’s movers: BlackBerry, Apple, Tesla

Aug. 12, 2013 at 4:30 p.m. ET
by Maria LaMagna










Stock futures knocked by Japan data, taper fears

Aug. 12, 2013 at 9:19 a.m. ET
by William L. Watts









Vical shares plunge 62% premarket after drug trial


Aug. 12, 2013 at 7:37 a.m. ET
by Saumya Vaishampayan









Vical off nearly 60% on drug disappointment


Aug. 12, 2013 at 7:30 a.m. ET
by Barbara Kollmeyer









Stocks to Watch Friday: Analogic, Werner


Sep. 13, 2012 at 4:36 p.m. ET
by David B. Wilkerson










Thursday’s biggest gaining and declining stocks

Sep. 13, 2012 at 3:39 p.m. ET
by MarketWatch









Friday’s biggest gaining and declining stocks


Jan. 6, 2012 at 4:44 p.m. ET
by Kate Gibson









Vical  slides 12% on stock offering


Jan. 6, 2012 at 11:56 a.m. ET
by Val Brickates Kennedy









Friday’s biggest gaining and declining stocks


Jul. 15, 2011 at 3:49 p.m. ET
by Kate Gibson









Vical jumps 7% on vaccine deal


Jul. 15, 2011 at 12:06 p.m. ET
by Val Brickates Kennedy










Google rallies after hours following results

Jul. 14, 2011 at 5:57 p.m. ET
by Carla Mozee









Vical, BioSante boost drug sector


Feb. 14, 2011 at 1:44 p.m. ET
by Val Brickates Kennedy









Friday’s biggest gaining and declining stocks


Sep. 24, 2010 at 2:44 p.m. ET
by MarketWatch









Wednesday’s biggest gaining and declining stocks


Sep. 22, 2010 at 7:37 p.m. ET
by MarketWatch









Biogen Idec and Vical shares fall


Sep. 22, 2010 at 11:42 a.m. ET
by Val Brickates Kennedy









Vical shares crushed by failed drug trial


Sep. 22, 2010 at 10:08 a.m. ET
by Val Brickates Kennedy









Thursday's biggest gaining and declining stocks


Feb. 11, 2010 at 4:46 p.m. ET
by MarketWatch









Monday's biggest gaining and declining stocks


Dec. 28, 2009 at 4:56 p.m. ET
by MarketWatch









Vical, Compugen lead drug stocks north


Dec. 28, 2009 at 12:59 p.m. ET
by Val Brickates Kennedy














Stocks to Watch: Darden, 3M, Sonic

Jun. 23, 2015 at 9:37 a.m. ET
on The Wall Street Journal









Vical’s Herpes Vaccine Didn’t Meet Primary Endpoint


Jun. 22, 2015 at 5:05 p.m. ET
on The Wall Street Journal









Stocks Finish Flat


Aug. 12, 2013 at 4:20 p.m. ET
on The Wall Street Journal









Stocks to Watch: BlackBerry, Vical, Steinway


Aug. 12, 2013 at 9:51 a.m. ET
on The Wall Street Journal










Stocks to Watch: Apple, K12, Pall Corp

Sep. 13, 2012 at 9:08 a.m. ET
on The Wall Street Journal









Satyam Computer Services, Vical: Biggest Price Decliners (SAY, VICL)


Sep. 24, 2010 at 12:51 p.m. ET
on The Wall Street Journal









iStar Financial, Vical: Biggest Price Decliners (SFI, VICL)


Sep. 22, 2010 at 4:56 p.m. ET
on The Wall Street Journal









iStar Financial, Vical: Biggest Price Decliners (SFI, VICL)


Sep. 22, 2010 at 12:56 p.m. ET
on The Wall Street Journal









BioSante Falls, Schnitzer Sinks


Jun. 30, 2009 at 8:46 p.m. ET
on The Wall Street Journal









New Tack With Bird-Flu Vaccine


Jul. 17, 2008 at 12:01 a.m. ET
on The Wall Street Journal









Harvest Natural Resources, Vical: Biggest Price Gainers (HNR, VICL)


Jun. 18, 2007 at 4:42 p.m. ET
on The Wall Street Journal









Shares of Some Banks Show Weakness


Oct. 21, 2006 at 12:01 a.m. ET
on The Wall Street Journal









Blue Dolphin and EpiCept Jump


Apr. 1, 2006 at 12:01 a.m. ET
on The Wall Street Journal









Skyworks, Kopin, Zoran Decline


Oct. 12, 2005 at 12:01 a.m. ET
on The Wall Street Journal









NIH to Launch Study of AIDS Vaccine


Oct. 11, 2005 at 8:01 p.m. ET
on The Wall Street Journal









DNA-Based Vaccines May Help Humans


Sep. 23, 2005 at 12:01 a.m. ET
on The Wall Street Journal









Innogenetics Carves Out Niche


Jul. 8, 2004 at 12:01 a.m. ET
on The Wall Street Journal









Input/Output, Superior Energy Rise


Feb. 10, 2004 at 7:25 p.m. ET
on The Wall Street Journal









Standard Pacific, Beazer Tumble


Jul. 15, 2003 at 8:49 p.m. ET
on The Wall Street Journal









Upgrades Boost Small Caps


Jul. 2, 2003 at 9:22 p.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More
Stocks were indicated to open slightly lower on Monday after some of the top momentum and crowded technology companies took it on the chin on Friday. Still, a rotation took place into more stable names and into other sectors as the top market darlings slid. This bull market is now over eight years old and [ ]

Jun. 12, 2017 at 8:17 a.m. ET
on 247WallSt.com





Premarket analyst action - healthcare
Premarket analyst action - healthcare

Jun. 12, 2017 at 8:59 a.m. ET
on Seeking Alpha





10-Q: VICAL INC
10-Q: VICAL INC

May. 15, 2017 at 3:34 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q1 2017 Results - Earnings Call Transcript
Vical's (VICL) CEO Vijay Samant on Q1 2017 Results - Earnings Call Transcript

May. 15, 2017 at 3:14 p.m. ET
on Seeking Alpha





Vical completes enrollment in mid-stage study of HSV-2 vaccine


Apr. 19, 2017 at 6:50 a.m. ET
on Seeking Alpha





Premarket Gainers as of 9:05 am


Apr. 5, 2017 at 9:25 a.m. ET
on Seeking Alpha





Vical inks hep B research deal with AnGes MG; shares ahead 11% premarket


Apr. 5, 2017 at 8:31 a.m. ET
on Seeking Alpha





Vical (VICL) Presents At 29th Annual ROTH Conference


Mar. 16, 2017 at 2:10 p.m. ET
on Seeking Alpha





10-K: VICAL INC


Mar. 10, 2017 at 4:05 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call Transcript


Mar. 10, 2017 at 12:46 a.m. ET
on Seeking Alpha





Is The Big Crash Coming? Why The Market Continues To Run


Mar. 1, 2017 at 2:41 p.m. ET
on Seeking Alpha





Vical: A Risky Net-Net Provides The Potential For A Profitable Swing Trade


Jan. 10, 2017 at 11:25 a.m. ET
on Seeking Alpha





52 Biotechnology Stocks to Sell Now


Nov. 14, 2016 at 9:00 a.m. ET
on InvestorPlace.com





27 Biotechnology Stocks to Sell Now


Nov. 7, 2016 at 8:45 a.m. ET
on InvestorPlace.com





10-Q: VICAL INC


Nov. 4, 2016 at 2:34 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





The Best Net-Net Stocks On Wall-Street Today


Nov. 4, 2016 at 8:51 a.m. ET
on Seeking Alpha





Vical's (VICL) CEO Vijay Samant on Q3 2016 Results - Earnings Call Transcript


Nov. 3, 2016 at 2:34 p.m. ET
on Seeking Alpha





Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study


Sep. 20, 2016 at 4:16 p.m. ET
on Zacks.com





Biotech Forum Daily Digest: FDA Finally Caves On Sarepta. Biotech Rally Continues. Spotlight On Sage Therapeutics


Sep. 19, 2016 at 2:54 p.m. ET
on Seeking Alpha





Hottest Manufacturing Stocks Now – SRPT TANH SORL PTCT


Sep. 19, 2016 at 10:30 a.m. ET
on InvestorPlace.com









Vical to Provide Company Update at the 2017 BIO International Convention
Vical to Provide Company Update at the 2017 BIO International Convention

Jun. 15, 2017 at 4:05 p.m. ET
on GlobeNewswire





Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

Jun. 5, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting

May. 23, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network: Vical Incorporated to Host Earnings Call
Investor Network: Vical Incorporated to Host Earnings Call

May. 15, 2017 at 9:00 a.m. ET
on ACCESSWIRE





Vical Reports First Quarter 2017 Financial Results
Vical Reports First Quarter 2017 Financial Results

May. 15, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017
Investor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017

May. 12, 2017 at 4:09 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results

May. 8, 2017 at 6:30 a.m. ET
on GlobeNewswire





Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day

May. 2, 2017 at 4:36 p.m. ET
on GlobeNewswire





Vical to Host Virtual Research & Development Day on May 2, 2017


Apr. 24, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial


Apr. 19, 2017 at 6:30 a.m. ET
on GlobeNewswire





Vical to Provide Company Update at the 29th Annual ROTH Conference


Mar. 10, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical to Provide Company Update at BIO Asia International Conference


Mar. 9, 2017 at 7:01 a.m. ET
on GlobeNewswire





Vical Reports Fourth Quarter 2016 Financial Results


Mar. 9, 2017 at 6:30 a.m. ET
on GlobeNewswire





Investor Network Invites You to the Vical Fourth Quarter 2016 Earnings Webcast Live on Thursday, March 9, 2017


Mar. 8, 2017 at 4:11 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results


Mar. 2, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Provides Company Update at Biocom's Global Life Science Partnering Conference


Feb. 24, 2017 at 3:00 p.m. ET
on GlobeNewswire





Vical Provides Company Update at BIO CEO and Investor Conference


Feb. 7, 2017 at 6:31 a.m. ET
on GlobeNewswire





Vical Reports Third Quarter 2016 Financial Results


Nov. 3, 2016 at 6:31 a.m. ET
on GlobeNewswire





Investor Calendar Invites You to the Vical Third Quarter 2016 Earnings Webcast Live on Thursday, November 3, 2016


Nov. 2, 2016 at 4:25 p.m. ET
on ACCESSWIRE





Vical Announces News Release and Conference Call Schedule for Third Quarter 2016 Financial Results


Oct. 27, 2016 at 6:31 a.m. ET
on GlobeNewswire











Vical Inc.


            
            Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. The company's pipeline consists of ASP0113 Therapeutic CMV Vaccine, CyMVectin Prophylactic CMV Vaccine and VL-2397 Antifungal. Vical was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.

            
            (See Full Profile)


  




Analyst Ratings



Sell
Under
Hold
Over
Buy

Number of Ratings 2
Full Ratings 





Benzinga's Top Initiations


Jul. 19, 2016 at 9:26 a.m. ET
on Benzinga.com





 


Competitors




Name
Chg %
Market Cap




Celldex Therapeutics Inc.
0.00%
$287.74M


Bristol-Myers Squibb Co.
1.90%
$88.95B


Pfizer Inc.
0.45%
$196.94B


Sanofi ADR
-1.10%
$120.91B


Merck & Co. Inc.
0.66%
$174.2B




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





DVAX

0.00%








S

0.24%








SSTI

-0.08%








MO

-9.49%








TRUE

1.33%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.























Bing Places for Business
























































































































Bing
 places for business


Sign in using your




Microsoft Account





Work Account





Google Account





Facebook Account

Don't have an account? Create one.





Stocks Index - Markets Index
























Bulletin






Investor Alert



















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




11:29 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



















































Stocks Index - Markets Index
























Bulletin






Investor Alert



















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




11:29 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



























































 



  VICL:NASDAQ CM Stock Quote - Vical Inc - Bloomberg Markets                     



     Error: Could not add to watchlist. X   + Watchlist  Vical Inc   VICL:US   NASDAQ CM        2.580USD   0.040   1.53%     As of 8:10 PM EDT 7/28/2017     Open   2.594    Day Range   2.580 - 2.690    Volume   41,560    Previous Close   2.620    52Wk Range   2.050 - 4.500    1 Yr Return   -37.83%                   


                Before it's here, it's on the Bloomberg Terminal.
            

                Learn More
            

         Open   2.594    Day Range   2.580 - 2.690    Volume   41,560    Previous Close   2.620    52Wk Range   2.050 - 4.500    1 Yr Return   -37.83%    YTD Return   12.17%    Current P/E Ratio (TTM)   -    Earnings per Share (USD) (TTM)   -0.880    Market Cap (m USD)   28.628    Shares Outstanding  (m)   11.096    Price/Sales (TTM)   2.03    Dividend Indicated Gross Yield   -        Sector Health Care   % Price Change +0.50%     Industry Pharmaceuticals, Biotechnology & Life Sciences   % Price Change +0.46%                    Related Videos  There are currently no related videos for this ticker. Please check back later.    Company News Press Releases   There are currently no news stories for this ticker. Please check back later.     6/15/2017   Vical to Provide Company Update at the 2017 BIO International Convention     6/5/2017   Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2     5/30/2017   Aspergillosis Pipeline Market Global Analysis and Therapeutics Development H1 2017 Report now Available at     5/23/2017   Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting     5/15/2017   Vical Reports First Quarter 2017 Financial Results     5/8/2017   Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results     5/2/2017   Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day     5/1/2017   Richard Kenney, MD, FACP, Joins TapImmune to Lead the Clinical Development Program     4/24/2017   Vical to Host Virtual Research & Development Day on May 2, 2017     4/19/2017   Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial    There are currently no press releases for this ticker. Please check back later.      Profile   Vical Incorporated develops gene-based pharmaceutical products for human therapy.  The Company develops cancer product candidates, as well as develops vaccines for infectious diseases and gene-based delivery of therapeutic proteins for other disorders.    Address  10390 Pacific Center CourtSan Diego, CA 92121-4340United States   Phone  1-858-646-1100   Website   www.vical.com     Executives Board Members    Vijay B Samant  President/CEO    Anthony A Ramos  CFO/Chief Acctg Officer    Mammen P Mammen  Senior VP:Clinical Development    Larry R Smith  Senior VP:Research    Keith D Hall  VP:Operations     Show More         







 VICL - Stock quote for Vical Inc - MSN Money















msn  back to msn home

money










web search














Sign in








Change language & content:

América Latina (español)
Argentina (español)
Australia (English)
België (Nederlands)
Belgique (français)
Brasil (português)
Canada (English)
Canada (français)
Chile (español)
Colombia (español)
Danmark (Dansk)
Deutschland (Deutsch)
España (español)
France (français)
India (English)
Indonesia (Bahasa Indonesia)
Ireland (English)
Italia (italiano)
Malaysia (English)
México (español)
Nederland (Nederlands)
New Zealand (English)
Norge (norsk, bokmål)
Österreich (Deutsch)
Perú (español)
Philippines (English)
Polska (polski)
Portugal (Português)
Schweiz (Deutsch)
Singapore (English)
South Africa (English)
Suisse (français)
Suomi (suomi)
Sverige (svenska)
Türkiye (Türkçe)
United Arab Emirates (English)
United Kingdom (English)
United States (English)
United States (español)
Venezuela (español)
Việt Nam (Tiếng Việt)
Ελλάδα (ελληνικά)
Россия (Pусский)
ישראל (עברית)‏
الإمارات العربية المتحدة (العربية‏)
المملكة العربية السعودية (العربية‏)
مصر (العربية‏)
ไทย (ไทย)
한국 (한국어)
中华人民共和国 (简体中文)
台灣 (繁體中文)
日本 (日本語)
香港特别行政區 (繁體中文)



Switch to Latino (Español)



 Feedback



Help






























AdChoices














Vical Inc
NASDAQ: VICL



US Markets Closed










AdChoices








2.58


▼


-0.04
-1.53%



After Hours : 
2.62
+0.04
+1.55%



 July 28, 2017 4:00 PM EDT. Delayed 15 minutes; Source: NASDAQ. Currency In USD                
















Save














            Summary
        



            Financials
        



            Analysis
        



            Options
        



            Ownership
        



            Company
        



            History
        



            Related
        


















































Open
2.59


Previous Close
2.62


Volume (Avg) 
41.56k (69.18k)


Day's Range
2.58-2.69


52Wk Range
2.05-4.50


Market Cap.
28.63M


Dividend Rate ( Yield)
-


Beta
2.12


Shares Outstanding
11.10M


P/E Ratio (EPS)
-









Recent News







Melanoma Drugs Market: Industry Overview and Key Factors

                            
                            openpr.com
                        
4 days ago






Somewhat Positive News Coverage Very Likely to Affect Vical (VICL) Share Price

                            
                            Breeze
                        
7/21/2017






Somewhat Favorable Media Coverage Very Likely to Affect Vical (VICL) Share Price

                            
                            Breeze
                        
7/16/2017






Negative Press Coverage Extremely Likely to Affect Vical (NASDAQ:VICL) Stock Price

                            
                            BNS
                        
7/6/2017






Vical (VICL) Reaches $2.71 After 4.00% Down Move, Wintrust Financial (WTFC) Had 4 Bulls

                            
                            Thorold News
                        
6/30/2017






Vical (VICL) Given Coverage Optimism Rating of 0.25

                            
                            themarketsdaily.com
                        
6/20/2017








HC Wainwright Analysts Give Vical Incorporated (VICL) a $9.00 Price Target

                            
                            BNS
                        
6/20/2017






Vical to Provide Company Update at the 2017 BIO International Convention

                            
                            einpresswire.com
                        
6/15/2017






Vical Inc (NASDAQ:VICL) Rating Reaffirmed

                            
                            presstelegraph.com
                        
6/15/2017






H.C. Wainwright Reiterates a Buy Rating on Vical Inc

                            
                            markets.co
                        
6/12/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            PipelineReview.com
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            TMCnet.com
                        
6/5/2017








BRIEF-Vical presents phase 1 VL-2397 data at June ASM microbe 2017 meeting supporting advancement to phase 2

                            
                            Business Insider
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            GlobeNewswire
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            NASDAQ
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            Benzinga
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            www.pm360online.com
                        
6/5/2017






Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2

                            
                            military-technologies.net
                        
6/5/2017























AdChoices
















AdChoices

















AdChoices




















Markets











DOW

DOW



▲

21,830.31


+33.76
+0.15%













Last updated time
7/28/2017 4:38 PM EDT







Markets





NASDAQ

NASDAQ



▼

6,374.68




-7.51
-0.12%










FTSE 100

FTSE 100



▼

7,368.37




-74.64
-1.00%










NYSE Composite

NYSE Composite



▼

11,954.69




-8.54
-0.07%



















AdChoices
















                Feedback
            







Send Feedback
Provide Feedback
Report a Problem


We appreciate your input!



Select a category:

I'm having problems with Top Destinations
I'm having issues searching
I'm having problems with Featured Apps
I see an error in the content
Other



How we can improve?





Please give an overall site rating:









Submit
Close


Privacy Statement


Help


Help & Support



 











 



Vical Inc. Executives, Organizational Chart, Company Profile Information, Contacts | Headquarters, Locations, News   












Submit

ContactCareersLogin

MENUtoggle
Our Difference Research Client SuccessWho We Serve Sales Professionals Marketing Professionals Executives Recruiting/Staffing ProfessionalsSolutions [Column]  ABM & ABS Actionable Intelligence Competitive Intelligence Customer Success & Retention  [Column]  Data Quality & Management Data Sets Integrations Lead Generation  [Column]  Predictive Analytics Sales & Marketing Alignment Targeting & Ranking Knowledge Hub Blog Case Studies Insights FAQsAbout Careers News Pricing

Menu

HomeOur Difference Research Client SuccessWho We Serve Sales Professionals Marketing Professionals Executives Recruiting/Staffing ProfessionalsSolutions ABM & ABS Actionable Intelligence Competitive Intelligence Customer Success & Retention Data Quality & Management Data Sets Integrations Lead Generation Predictive Analytics Sales & Marketing Alignment Targeting & RankingKnowledge Hub Blog Case Studies Insights FAQsAbout Careers News PricingGet a Free ProfileSchedule a DemoRequest PricingContact UsLogin
Home / Companies / Vical Inc.


Vical Inc.

10390 Pacific Center Court 
San Diego CA 92121 United States
Phone: +1 858-___-____
Fax: +1 858-___-____
http://www.vical.com





5
Managers




5
IT employees




$1.1MEST.
IT Budget




Vical Inc. develops technology using DNA for the prevention and treatment of serious or life-threatening diseases. It is headquartered in San Diego, CA and was founded in 1987.






Sector (Industry)
Healthcare & Pharmaceuticals (Biotech and Pharmaceuticals)


Employees
69


Revenue
$20.9M


FYE
12/31




Breaking news on investment signals




Date
Type
Inside Scoop






Want full access to this profile and more?
RainKing's clients have access to over 1,500 new investment signals published daily, which provide insights on spending initiatives, pain points, management changes and more from companies around the globe. Interested in becoming a client?
Request a demo
Request a quote




Technologies currently being used

IT
Marketing


Data Analytics/ Databases

Relational Databases
Microsoft Access

Web Analytics
comScoreCross PixelDatalogixGoogle Analytics (GA)Google Universal AnalyticsLotameOwnerIQ
Data Infrastructure

Cloud Systems
Citrix NetScaler

Email Hosting
Mimecast (mail server)

Hosting
IntermediaProlexic Technologies (Hosting)
Data Storage

Storage Management
Iron Mountain
Enterprise/ ERP

Enterprise Resource Planning (ERP)
Solarsoft

HRIS
Ceridian
Industry Software

Professional Services Software
Aggregate KnowledgeDstilleryQuickbooks
This is just a subset of the full Technolgies being used by this company.
Analytics

Web Analytics
Google Universal Analytics
Creative/ Content

Website Design
LinkedInButton
eCommerce

Social Commerce
Prolexic Technologies (Hosting)
Product/ Brand Mgmt

Mobile Application and Content Services
Twitter
Sales/ Mktg Automation

Email Marketing
Mimecast (mail server)
This is just a subset of the full Technolgies being used by this company.



Become a RainKing power-user today!
RainKing's rich data provides clients with a deeper understanding of who will be making – and what will be driving – upcoming investments in IT. Know what your prospects are planning before your competition does, and beat them to the negotiating table.
Request a demo
Request a quote




Org chart of IT decision makers




Nathan Sampson
Manager, Information Technology
___@vical.com
+1 858-___-____







Anthony Ramos
Vice President, Finance and Chief Accounting Officer
___@vical.com
+1 858-___-____







Larry Smith
Vice President, Vaccine Research
___@vical.com
+1 858-___-____



This is just a subset of the full Org Chart for this company.


Want access to this and more? Become a client today!
RainKing clients get access to all 615 decision makers in this company's org chart.
Request a demo
Request a quote








Want full access to this profile and more?
RainKing's clients have access to over 1,500 new investment signals published daily, which provide insights on spending initiatives, pain points, management changes and more from companies around the globe. Interested in becoming a client?
Request a demo
Request a quote









To receive a FREE PDF of this company, simply fill out the form below










Get your free company profile




Search





Subscribe to our newsletter



Connect with Us
 





 





 





 





 







 




7700 Old Georgetown Road
Bethesda, MD 20814-6100
1.866.592.7122
contactus@rainkingonline.com


 Sitemap Terms of Use Privacy Policy 


©2017 RainKing
























Vical Incorporated - Product Pipeline Review - 2015

















































































ABOUT US
BLOG
CONTACT US
FAQ























USD
EUR
GBP



USD 
▼

USD
EUR
GBP






€
EUR
$
USD
£
GBP







+353-1-416-8900REST OF WORLD



1-800-526-8630U.S. (TOLL FREE)








 




Advanced








Price From: 
€1329EUR$1,500USD£1,187GBP 
View Pricing






 Home
/






Categories
/






Company Reports











 
SELECT A FORMAT








€1329EUR$1,500USD£1,187GBP



                                                        Single User
                                                         Electronic (PDF)






                                                                            
                                                                            This is a single user license, allowing one specific user access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€2657EUR$3,000USD£2,374GBP



                                                        Site License
                                                         Electronic (PDF)






                                                                            
                                                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                










€3986EUR$4,500USD£3,561GBP



                                                        Enterprisewide
                                                         Electronic (PDF)






                                                                            
                                                                            This is an enterprise license, allowing all employees within your organisation access to the product. The report will be emailed to you.  The report is sent in PDF format. 

                                                







  ADD TO BASKET




                                                                        order by fax
                                        

                                            need a quote ?
                                        



 

OUR CLIENTS












HAVE A QUESTION?
EMAIL US
VIEW FAQs



RECENTLY VIEWED PRODUCTS











Partner of Research and MarketsVACCINATING 40,000 CHILDREN IN 2017





WHY CHOOSE RESEARCH AND MARKETS?



WORLD'S LARGEST SELECTION




TRUSTED BY THE BEST




CUSTOMER FOCUSED




SAFE & SECURE







This the second time my company ordered reports from Research and Markets. The Customer Team responded

                         very fast and communication was excellent
                        
                    



                            READ MORE
                        


Samuel Tanudjaya
Assistant Manager
PT Synco Global















Vical Incorporated - Product Pipeline Review - 2015



ID: 3366196
Company Profile
July 2015
34 pages

Global Markets Direct                                

Vical Inc












DESCRIPTION


TABLE OF CONTENTS


SAMPLES


FORMATS







1 of 4











                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                                    Vical Incorporated - Product Pipeline Review - 2015SummaryThis, ‘Vical Incorporated - Product Pipeline Review - 2015’, provides an overview of the Vical Incorporated’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Vical Incorporated’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones- Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement- Latest news and deals relating to the Vical Incorporated’s pipeline productsReasons to buy- Evaluate Vical Incorporated’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Vical Incorporated in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Vical Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues
                                                                                

 SHOW LESS
                                                                                

 READ MORE
                                                                                



Note: Product cover images may vary from those shown




2 of 4







                            LOGIN TO ACCESS EXECUTIVE SUMMARY
                        



                            PRINTER FRIENDLY
                        



                            PRINTABLE PDF BROCHURE
                        

SEND TO A FRIEND






                                                                    List of TablesList of FiguresVical Incorporated SnapshotVical Incorporated OverviewKey InformationKey FactsVical Incorporated - Research and Development OverviewKey Therapeutic AreasVical Incorporated - Pipeline ReviewPipeline Products by Stage of DevelopmentPipeline Products - MonotherapyPipeline Products - Partnered ProductsPartnered Products/Combination Treatment ModalitiesPipeline Products - Out-Licensed ProductsOut-Licensed Products/Combination Treatment ModalitiesVical Incorporated - Pipeline Products GlanceVical Incorporated - Clinical Stage Pipeline ProductsPhase I Products/Combination Treatment ModalitiesVical Incorporated - Early Stage Pipeline ProductsIND/CTA Filed Products/Combination Treatment ModalitiesPreclinical Products/Combination Treatment ModalitiesVical Incorporated - Drug ProfilesVCLHB-01Product DescriptionMechanism of ActionR&D ProgressVCLHM-01Product DescriptionMechanism of ActionR&D ProgressCyMVectinProduct DescriptionMechanism of ActionR&D ProgressASP-2397Product DescriptionMechanism of ActionR&D Progressmeasles (bivalent) vaccineProduct DescriptionMechanism of ActionR&D ProgressVical Incorporated - Pipeline AnalysisVical Incorporated - Pipeline Products by TargetVical Incorporated - Pipeline Products by Route of AdministrationVical Incorporated - Pipeline Products by Molecule TypeVical Incorporated - Recent Pipeline UpdatesVical Incorporated - Dormant ProjectsVical Incorporated - Discontinued Pipeline ProductsDiscontinued Pipeline Product ProfilesHIV VaccineVical Incorporated - Company StatementVical Incorporated - Locations And SubsidiariesHead OfficeAppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer   List of TablesVical Incorporated, Key InformationVical Incorporated, Key FactsVical Incorporated - Pipeline by Indication, 2015Vical Incorporated - Pipeline by Stage of Development, 2015Vical Incorporated - Monotherapy Products in Pipeline, 2015Vical Incorporated - Partnered Products in Pipeline, 2015Vical Incorporated - Partnered Products/ Combination Treatment Modalities, 2015Vical Incorporated - Out-Licensed Products in Pipeline, 2015Vical Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015Vical Incorporated - Phase I, 2015Vical Incorporated - IND/CTA Filed, 2015Vical Incorporated - Preclinical, 2015Vical Incorporated - Pipeline by Target, 2015Vical Incorporated - Pipeline by Route of Administration, 2015Vical Incorporated - Pipeline by Molecule Type, 2015Vical Incorporated - Recent Pipeline Updates, 2015Vical Incorporated - Dormant Developmental Projects,2015Vical Incorporated - Discontinued Pipeline Products, 2015   List of FiguresVical Incorporated - Pipeline by Top 10 Indication, 2015Vical Incorporated - Pipeline by Stage of Development, 2015Vical Incorporated - Monotherapy Products in Pipeline, 2015Vical Incorporated - Partnered Products in Pipeline, 2015Vical Incorporated - Pipeline by Top 10 Target, 2015Vical Incorporated - Pipeline by Top 10 Molecule Type, 2015
                                                                
Note: Product cover images may vary from those shown




3 of 4





LOADING...







4 of 4






Note: Product cover images may vary from those shown








RELATED PRODUCTS 







Vical Inc (VICL) - Financial and Strategic SWOT Analysis Review


 SWOT Analysis
June 2017




FROM


€111EUR$125USD£99GBP







Corcept Therapeutics Incorporated - Product Pipeline Review - 2015


 Company Profile
May 2015




FROM


€1329EUR$1,500USD£1,187GBP







Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2015


 Company Profile
April 2015




FROM


€1329EUR$1,500USD£1,187GBP







Vertex Pharmaceuticals Incorporated - Product Pipeline Review - 2016


 Company Profile
March 2016




FROM


€1329EUR$1,500USD£1,187GBP







InSite Vision Incorporated - Product Pipeline Review - 2015


 Company Profile
June 2015




FROM


€1329EUR$1,500USD£1,187GBP







3SBio Inc. - Product Pipeline Review - 2015


 Company Profile
September 2015




FROM


€1329EUR$1,500USD£1,187GBP







Agenus, Inc. - Product Pipeline Review - 2016


 Company Profile
April 2016




FROM


€1329EUR$1,500USD£1,187GBP







Vernalis Plc - Product Pipeline Review - 2015


 Company Profile
December 2015




FROM


€1329EUR$1,500USD£1,187GBP







Allergan Plc - Product Pipeline Review - 2016


 Company Profile
March 2016




FROM


€1329EUR$1,500USD£1,187GBP







Actavis plc - Product Pipeline Review - 2015


 Company Profile
May 2015




FROM


€1329EUR$1,500USD£1,187GBP








 close

Vical Incorporated - Product Pipeline Review - 2015



 close

ASK A QUESTION

*Required Information
 
Product: Vical Incorporated - Product Pipeline Review - 2015


YOUR QUESTION*







YOUR CONTACT DETAILS*

Title
Mr
Mrs
Dr
Miss
Ms
Prof




First Name




Last Name




Email Address




Country
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




Phone Number



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998












We request your telephone number so we can contact you in the event we have difficulty reaching you via email.
                    We aim to respond to all questions on the same business day.





 



 close

SEND TO A FRIEND

* Required Information
 FRIEND'S DETAILS

Full Name*




Email Address*




Message to friend




YOUR CONTACT DETAILS

Full Name*




Email Address*













 


 close

Request a Quote

 
Please complete the below form and click "send request" to obtain a pdf quotation and order form.
This document will be available for immediate download and will also be emailed to you.
            
* Required Information


YOUR ADDRESS

Address 1*




Address 2




Address 3




City*




Postal/ZIP Code




Country*
Please Select
------------------------------
United States
United Kingdom
Germany
Canada
Australia
------------------------------
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica-Casey
Antarctica-Scott
Antigua and Barbuda
Argentina
Armenia
Aruba
Ascension Island
Ashmore and Cartier Islands
Atlantic East
Atlantic West
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burma
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Clipperton Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Cook Islands
Costa Rica
Croatia
Cuba
Curaco 
Cyprus
Czech Republic
Democratic Republic of Congo
Denmark
Djibouti
Dominica
Dominican Republic
East Timor
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Islas Malvinas)
Faroe Islands
Fiji Islands
Finland
France
French Guiana
French Polynesia
Gabon
Gambia
Gaza Strip
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote d'Ivoire)
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte Islands
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Islands
North Korea
Northern Ireland
Northern Marianas
Norway
Oman
Pakistan
Palau
Palestine
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russia
Rwanda
Saint Christopher Nevis
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome
Saudi Arabia
Scotland
Senegal
Serbia
Serbia and Montenegro
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Korea
Spain
Sri Lanka
Sudan
Suriname
Swaziland
Sweden
Switzerland
Syria
Tahiti
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Vatican City (Holy See)
Venezuela
Vietnam
Virgin Islands
Wallis And Futuna
West Bank
West Indies
Western Sahara
Yemen
Yugoslavia
Zaire
Zambia
Zimbabwe




State





YOUR DETAILS

Title*
Mr
Mrs
Dr
Miss
Ms
Prof




First Name*




Last Name*




Organisation*




Email Address*




Phone Number*



+1
+11
+1-242
+1-246
+1-264
+1-268
+1-284
+1-345
+1-441
+1-473
+1-649
+1-664
+1-670
+1-671
+1-684
+1-758
+1-767
+1-784
+1-787
+1-809
+1-868
+1-869
+1-876
+20
+212
+213
+216
+218
+220
+221
+222
+224
+225
+226
+227
+228
+229
+23
+230
+231
+232
+233
+234
+235
+236
+237
+238
+239
+240
+241
+242
+243
+244
+245
+247
+248
+249
+250
+251
+252
+253
+254
+255
+256
+257
+258
+260
+261
+263
+264
+265
+266
+267
+268
+269
+27
+284
+290
+291
+297
+298
+299
+30
+31
+32
+33
+34
+350
+351
+352
+353
+354
+355
+356
+357
+358
+359
+36
+370
+371
+372
+373
+374
+375
+376
+377
+378
+379
+380
+381
+382
+385
+386
+387
+389
+39
+40
+41
+420
+421
+423
+43
+44
+45
+46
+47
+48
+49
+500
+501
+502
+503
+504
+505
+506
+507
+509
+51
+52
+53
+54
+55
+56
+57
+58
+590
+591
+592
+593
+594
+595
+596
+597
+598
+599
+60
+61
+6101
+62
+63
+64
+65
+66
+670
+672
+673
+674
+675
+677
+678
+679
+680
+681
+682
+683
+685
+686
+687
+688
+689
+691
+692
+7
+81
+82
+84
+850
+852
+853
+855
+856
+86
+869
+871
+874
+880
+886
+90
+91
+92
+93
+94
+95
+960
+961
+962
+963
+964
+965
+966
+967
+968
+970
+971
+972
+973
+974
+975
+976
+977
+98
+992
+993
+994
+995
+996
+998











                                PO Number
                                (if applicable)







PRODUCT FORMAT




License
Format
Properties
Price




 
SINGLE USER Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a single user license, allowing one specific user access to the product.
                                        

€1329EUR$1,500USD£1,187GBP





 
SITE LICENSE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is a site license, allowing all users within a given geographical location of your organisation access to the product.
                                        

€2657EUR$3,000USD£2,374GBP





 
ENTERPRISEWIDE Electronic (PDF)                                                



                                            The report will be emailed to you.  The report is sent in PDF format. 
                                        

                                            This is an enterprise license, allowing all employees within your organisation access to the product.
                                        

€3986EUR$4,500USD£3,561GBP







* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.





 
























	Vical - Home












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04









Home



































Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on our patented DNA delivery technologies and other therapeutic approaches.





Latest




View all news
RECENT NEWS










June 15, 2017

Vical to Provide Company Update at the 2017 BIO International Convention











June 5, 2017

Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2














Latest




EVENTS & PRESENTATIONS
View all events & presentations







June 21, 2017
Vical Provides Company Update at the 2017 BIO International Convention

View the Webcast






May 15, 2017
Vical Inc. 1Q17 Financial Results Conference Call

View the Webcast













PRODUCT PIPELINE













About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    













	Vical - Products - Pipeline












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04











Products














Pipeline





ASP0113 Therapeutic CMV Vaccine





CyMVectin™ Prophylactic CMV Vaccine





VCL-HB01 Therapeutic HSV-2 Vaccine





VL-2397 Antifungal





Other Products






Apex®-IHN





Dengue Vaccine





ONCEPT®










PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalApex®-IHNDengue VaccineONCEPT®Other Products









Home / Products / Pipeline










 











About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    













	Vical - Home












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04









Home



































Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on our patented DNA delivery technologies and other therapeutic approaches.





Latest




View all news
RECENT NEWS










June 15, 2017

Vical to Provide Company Update at the 2017 BIO International Convention











June 5, 2017

Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2














Latest




EVENTS & PRESENTATIONS
View all events & presentations







June 21, 2017
Vical Provides Company Update at the 2017 BIO International Convention

View the Webcast






May 15, 2017
Vical Inc. 1Q17 Financial Results Conference Call

View the Webcast













PRODUCT PIPELINE













About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    













	Vical - Contact Us - Directions to Vical












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04











Contact Us














Contact Info





Directions to Vical





Careers










Contact InfoDirections to VicalCareers









Home / Contact Us / Directions to Vical









Directions to Vical

Vical Incorporated10390 Pacific Center CourtSan Diego, CA 92121-4340
View Larger Map










About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    















    VICL Key Statistics - Vical Inc. Financial Ratios - MarketWatch




































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Vical Inc.

                  NASDAQ: VICL
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Vical Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 28, 2017, 3:59 p.m.


VICL

/quotes/zigman/71880444/composite


$
2.58




Change

-0.04
-1.53%

Volume
Volume 41,560
Quotes are delayed by 20 min








/quotes/zigman/71880444/composite
Previous close

$
			2.62
		


$
				2.58
			
Change

-0.04
-1.53%





Day low
Day high
$2.58
$2.69










52 week low
52 week high

            $2.05
        

            $4.50
        

















			Company Description 


			Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into p...
		


                Vical, Inc. is a biopharmaceutical company. The company engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. The company's pipeline consists of ASP0113 Therapeutic CMV Vaccine, CyMVectin Prophylactic CMV Vaccine and VL-2397 Antifungal. Vical was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA.
            




Valuation

P/E Current
-2.93


P/E Ratio (with extraordinary items)
-3.13


Price to Sales Ratio
1.59


Price to Book Ratio
0.56


Enterprise Value to EBITDA
1.17


Enterprise Value to Sales
-0.72

Efficiency

Revenue/Employee
199,055.00


Income Per Employee
-122,918.00


Total Asset Turnover
0.28

Liquidity

Current Ratio
6.70


Quick Ratio
6.70


Cash Ratio
5.45



Profitability

Gross Margin
56.71


Operating Margin
-63.15


Pretax Margin
-61.75


Net Margin
-61.75


Return on Assets
-17.56


Return on Equity
-19.82


Return on Total Capital
-19.82


Return on Invested Capital
-19.82

Capital Structure




      Officers and Executives
    



Name
Age
Officer Since
Title





Mr. Vijay B. Samant 
63
2000
President, Chief Executive Officer & Director



Mr. Keith D. Hall 
-
2016
Vice President-Operations



Mr. Anthony Alan Ramos 
50
2005
Chief Financial & Accounting Officer



Dr. Lawrence Russell Smith 
55
2003
Vice President-Vaccine Research



Dr. Mammen P. Mammen 
52
2012
Vice President-Clinical Vaccines





Insider Actions


 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}



/news/latest/company/us/vicl

      MarketWatch News on VICL
    





J.C. Penney and more of the year's most profitable shorts

4:51 p.m. Dec. 9, 2013
 - blogs.marketwatch.com




 Monday’s movers: BlackBerry, Apple, Tesla
4:29 p.m. Aug. 12, 2013
 - Maria LaMagna




 Stock futures knocked by Japan data, taper fears
9:18 a.m. Aug. 12, 2013
 - William L. Watts




 Vical shares plunge 62% premarket after drug trial
7:36 a.m. Aug. 12, 2013
 - Saumya Vaishampayan




 Vical off nearly 60% on drug disappointment
7:29 a.m. Aug. 12, 2013
 - Barbara Kollmeyer




 Stocks to Watch Friday: Analogic, Werner
4:35 p.m. Sept. 13, 2012
 - David B. Wilkerson




 Thursday’s biggest gaining and declining stocks
3:38 p.m. Sept. 13, 2012
 - MarketWatch




 Friday’s biggest gaining and declining stocks
5:43 p.m. Jan. 6, 2012
 - Kate Gibson




 Vical  slides 12% on stock offering
12:56 p.m. Jan. 6, 2012
 - Val Brickates Kennedy




 Friday’s biggest gaining and declining stocks
3:48 p.m. July 15, 2011
 - Kate Gibson




 Vical jumps 7% on vaccine deal
12:06 p.m. July 15, 2011
 - Val Brickates Kennedy




 Google rallies after hours following results
5:57 p.m. July 14, 2011
 - Carla Mozee




 Vical, BioSante boost drug sector
2:44 p.m. Feb. 14, 2011
 - Val Brickates Kennedy




 Friday’s biggest gaining and declining stocks
2:43 p.m. Sept. 24, 2010
 - MarketWatch




 Wednesday’s biggest gaining and declining stocks
7:36 p.m. Sept. 22, 2010
 - MarketWatch




 Biogen Idec and Vical shares fall
11:41 a.m. Sept. 22, 2010
 - Val Brickates Kennedy




 Vical shares crushed by failed drug trial
10:08 a.m. Sept. 22, 2010
 - Val Brickates Kennedy




 Thursday's biggest gaining and declining stocks
5:46 p.m. Feb. 11, 2010
 - MarketWatch




 Monday's biggest gaining and declining stocks
5:56 p.m. Dec. 28, 2009
 - MarketWatch




 Vical, Compugen lead drug stocks north
1:59 p.m. Dec. 28, 2009
 - Val Brickates Kennedy


Loading more headlines...







/news/nonmarketwatch/company/us/vicl

      Other News on VICL
    





Premarket analyst action - healthcare

8:59 a.m. June 12, 2017
 - Seeking Alpha





Top Analyst Upgrades and Downgrades: Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna, Lexicon Pharma and Many More

9:06 a.m. June 12, 2017
 - 247WallSt.com




 10-Q: VICAL INC
3:34 p.m. May 15, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q1 2017 Results - Earnings Call Transcript

3:14 p.m. May 15, 2017
 - Seeking Alpha





Vical completes enrollment in mid-stage study of HSV-2 vaccine

6:50 a.m. April 19, 2017
 - Seeking Alpha





Premarket Gainers as of 9:05 am

9:25 a.m. April 5, 2017
 - Seeking Alpha





Vical inks hep B research deal with AnGes MG; shares ahead 11% premarket

8:31 a.m. April 5, 2017
 - Seeking Alpha





Vical (VICL) Presents At 29th Annual ROTH Conference

2:10 p.m. March 16, 2017
 - Seeking Alpha




 10-K: VICAL INC
5:05 p.m. March 10, 2017
 - Edgar Online -  (EDG = 10Q, 10K)





Vical's (VICL) CEO Vijay Samant on Q4 2016 Results - Earnings Call Transcript

1:46 a.m. March 10, 2017
 - Seeking Alpha





Is The Big Crash Coming? Why The Market Continues To Run

3:41 p.m. March 1, 2017
 - Seeking Alpha





Vical: A Risky Net-Net Provides The Potential For A Profitable Swing Trade

12:25 p.m. Jan. 10, 2017
 - Seeking Alpha





52 Biotechnology Stocks to Sell Now

10:00 a.m. Nov. 14, 2016
 - InvestorPlace.com





27 Biotechnology Stocks to Sell Now

9:45 a.m. Nov. 7, 2016
 - InvestorPlace.com




 10-Q: VICAL INC
2:33 p.m. Nov. 4, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





The Best Net-Net Stocks On Wall-Street Today

8:51 a.m. Nov. 4, 2016
 - Seeking Alpha





Vical's (VICL) CEO Vijay Samant on Q3 2016 Results - Earnings Call Transcript

2:34 p.m. Nov. 3, 2016
 - Seeking Alpha





Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study

4:16 p.m. Sept. 20, 2016
 - Zacks.com





Biotech Forum Daily Digest: FDA Finally Caves On Sarepta. Biotech Rally Continues. Spotlight On Sage Therapeutics

2:54 p.m. Sept. 19, 2016
 - Seeking Alpha





Hottest Manufacturing Stocks Now – SRPT TANH SORL PTCT

10:30 a.m. Sept. 19, 2016
 - InvestorPlace.com


Loading more headlines...












At a Glance

Vical, Inc.
10390 Pacific Center Court


San Diego, California 92121-4340




Phone
1 8586461100


Industry
Biotechnology


Sector
Health Care/Life Sciences


Fiscal Year-end
12/2017


View SEC Filings




Revenue
$14.53M


Net Income
$-8.97M


Employees

        73.00


Annual Report for VICL











/news/pressrelease/company/us/vicl

      Press Releases on VICL
    




 Vical to Provide Company Update at the 2017 BIO International Convention
4:05 p.m. June 15, 2017
 - GlobeNewswire




 Vical Presents Phase 1 VL-2397 Data at the June ASM Microbe 2017 Meeting Supporting Advancement to Phase 2
6:31 a.m. June 5, 2017
 - GlobeNewswire




 Vical to Present VL-2397 Data at the June ASM Microbe 2017 Meeting
6:30 a.m. May 23, 2017
 - GlobeNewswire




 Investor Network: Vical Incorporated to Host Earnings Call
9:00 a.m. May 15, 2017
 - ACCESSWIRE




 Vical Reports First Quarter 2017 Financial Results
6:30 a.m. May 15, 2017
 - GlobeNewswire




 Investor Network Invites You to the Vical First Quarter 2017 Earnings Webcast Live on Monday, May 15, 2017
4:09 p.m. May 12, 2017
 - ACCESSWIRE




 Vical Announces News Release and Conference Call Schedule for First Quarter 2017 Financial Results
6:30 a.m. May 8, 2017
 - GlobeNewswire




 Vical Highlights Successful Outcome of Phase 1 Trial of VL-2397 Novel Antifungal During its Research and Development Day
4:36 p.m. May 2, 2017
 - GlobeNewswire




 Vical to Host Virtual Research & Development Day on May 2, 2017
6:30 a.m. April 24, 2017
 - GlobeNewswire




 Vical Completes Target Enrollment in Its Phase 2 Therapeutic HSV-2 Vaccine Trial
6:30 a.m. April 19, 2017
 - GlobeNewswire




 Vical to Provide Company Update at the 29th Annual ROTH Conference
7:30 a.m. March 10, 2017
 - GlobeNewswire




 Vical to Provide Company Update at BIO Asia International Conference
8:01 a.m. March 9, 2017
 - GlobeNewswire




 Vical Reports Fourth Quarter 2016 Financial Results
7:30 a.m. March 9, 2017
 - GlobeNewswire




 Investor Network Invites You to the Vical Fourth Quarter 2016 Earnings Webcast Live on Thursday, March 9, 2017
5:10 p.m. March 8, 2017
 - ACCESSWIRE




 Vical Announces News Release and Conference Call Schedule for Fourth Quarter 2016 Financial Results
7:30 a.m. March 2, 2017
 - GlobeNewswire




 Vical Provides Company Update at Biocom's Global Life Science Partnering Conference
4:00 p.m. Feb. 24, 2017
 - GlobeNewswire




 Vical Provides Company Update at BIO CEO and Investor Conference
7:30 a.m. Feb. 7, 2017
 - GlobeNewswire




 Vical Reports Third Quarter 2016 Financial Results
6:31 a.m. Nov. 3, 2016
 - GlobeNewswire




 Investor Calendar Invites You to the Vical Third Quarter 2016 Earnings Webcast Live on Thursday, November 3, 2016
4:25 p.m. Nov. 2, 2016
 - ACCESSWIRE




 Vical Announces News Release and Conference Call Schedule for Third Quarter 2016 Financial Results
6:30 a.m. Oct. 27, 2016
 - GlobeNewswire


Loading more headlines...









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/65801738/composite TLT+1.11%


/quotes/zigman/59386294/composite JNUG-5.94%


X




Powered by














Log In




11:29 PM EDT
July 28, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
9:16pWall Street isn’t ready for a 1,100-point tumble in the Dow industrials
7:39pBarron's Buzz: Robo 2.0, Facebook and Twitter, Trading On News
7:29pA Wild Week in Washington 
6:32pThe dark side of cruises
6:32pThe highest paid athletes in the world, in one chart
6:31pO.J. Simpson made over $400,000 while in prison and won’t have to give any of it to the Goldman family
6:31p Trump to Police: 'Don't Be Too Nice'
6:31pHere are 10 co-workers you should avoid like the plague — especially in meetings
6:29pTop 10 most annoying people you may want to unfriend on Facebook 
6:29pThis is one person you should never unfriend on Facebook...
6:29p3 horrible ways typos could alter the course of your life
6:27pPaint your bathroom this color and boost your home’s selling price by $5,400
6:27pAmericans’ new badge of honor: ‘I was blocked by a celebrity!’
6:27p5 weird things I found out about America in my first 24 hours 
6:14pBeyond Tesla: 7 stocks driving the autonomous car revolution
6:14pThese 7 highly taxed companies need Congress to finally act on tax reform
6:11pWatch out: ‘Kids’ are making the most money in this stock market 
6:10p7 real ways for millennials to save money (not by brownbagging and skipping Starbucks)
6:09p‘Game of Thrones’: This computer model predicts who will be killed off — or survive
6:09pThis basic balanced index fund is beating the hedge fund averages
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,830.31

+33.76
+0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,374.68

-7.51
-0.12%





s&p 500

/quotes/zigman/3870025/realtime
2,472.10

-3.32
-0.13%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


























































            Vical Inc - San Diego 92121 (San Diego County), 10390 Pacific Center Cour...



































































                    Company directory and business data solutions



About Kompass







                                        Register






                                        Login







                                                    Login
×



                                                    Please fill in your login and password







Register
Login


Forgot your password ?


























								English

























Contact Kompass North America
Please contact one of our team of experts from Monday to Friday between 9am and 5pm or by email




+1 609 785 5986





Contact us











                    Search across 10.5 million selected companies  in more than  60 countries.

















or




all
suppliers
one company











Rechercher















                                    Data Access



Business solutions 
Sales leads? Online promotion?


EasyBusiness
EasyList


                        Free Guide - B2B Prospecting Success




                        KompassPublicTenders




                        Credit Card Payment 




                        Webinar



                                   Digital solutions
Booster
Promotional solutions
Register your company




See all business solutions

Videos & Tutorials

Quizz




EasyBusiness
Find the right sales leads!

                                With more than 10.5 million companies and 60 search criteria, our global B2B database, EasyBusiness, will help you find the right customer leads and marketing lists.
Find out more >


EasyList
Need help with finding prospects?
EasyList is our straightforward on demand tool designed to help you build personalised company lists from a global database of 9 million companies.
Find out more


Register your company
Build your free company profile!
If you are looking to expand into new markets or want to grow your sales activity, then register your company free of charge on the global Kompass B2B directory.
Find out more >


Booster
Engage your target audience!
Engage your target audience and attract new business leads using the Kompass.com our global online digital directory. With over 6m visitors per month from 69 countries worldwide, let us improve your SEO and increase your customer traffic.
Find out more >


Promotional solutions
Attract relevant enquiries!
Build, enhance and manage your company profile to attract visitors instantly. Use our PPC experts to help drive relevant enquiries through to your profile – cost effective, managed and GUARANTEED.
Find out more >


Free Guide
B2B Prospecting Success
Best Strategy To Find Targeted Leads And Drive Great Sales Results
 


PublicTenders
PublicTenders
Public Tenders
 


Payment Portal
Payment Portal
Credit Card Payment Portal
 


Webinar: Skyrocketing your Government Contracting
Public Tenders Webinar
Learn about the value of selling to the US Government, key market challenges, and how to find and respond to opportunities throughout the USA - Plus get three months free access to the database!
 

















California






San Diego County




                                              Vical Inc





x


Every month we have millions of visitors on Kompass, looking for companies like yours. Register your company on Kompass and build your FREE company profile to attract those visitors.


Register


Login


Login








                        Vical Inc





                                            10390 Pacific Center Court 

                                    San Diego CA 92121
United States







     Need to contact this company?




Call
Click to see their phone number








Call
Click to see their phone number















---




						Service 
						
						+ call price





* This phone number available for 3 min is not the recipient's number but a number from a service which will put you through to that person.
				This service is produced by Kompass. 
                					Why this number ?
















Service & free calls*






* This number, only available 3 minutes, is not your correspondant's number but the number of a service putting you through to that person.
This service is produced by Kompass. 
									Why this number ?










All the lines are busy at the moment, please try again in a moment.













                                    View map location






                                        View their website




Purchase online company lists of companies

Create your prospect list >











                        Vical Inc
×













                        Addresses of : Vical Inc

×

























                            Description



                            Key figures



                                    Executives



                                    Activities











Description
Key figures
Executives
Activities







						Company Summary

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (Dna) delivery technologies for the prevention and treatment of serious or life-threatening diseases. In addition, the Company has gained access to enhancing technologies through licensing and collaborative agreements. Vical, together with its licensees and collaborators, is developing a number of Dna-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cardiovascular diseases and cancer. As of December 31, 2005, the Company's independent development focus is on its novel plasmids (pdna) vaccines for cytomegalovirus (Cmv) and avian influenza, as well as its cancer immunotherapeutic, Il-2 Ep. All of Vical's potential products are in research and development phases. No revenues have been generated from the sale of any such products.
Vical, Inc. is a biopharmaceutical firm that develops vaccines for the prevention and treatment of viruses and various forms of cancer based on its dna delivery technology.




					General Information




									Year established
1987



                                Type of company

							 Head Office



									Fax

										
											+1 858 646-1150 (FPS)



									Website

http://www.vical.com









Key figures



            Employees










                        Company

                        100-249 Employees






                Turnover




                                                2008 
5 to 10 million USD







Executives



			Executive information


 

Download the executives list











												Jill  Church



										Chief Financial Officer










												R. D.
											



										Chairman Emeritus










												V. S.
											



										President; President, CEO, and Director










												R. J.
											



										Senior Vice President; SVP Business Operations










												A. R.
											



										Senior Vice President










												V. S.
											



										President and Chief Executive Officer










												A. R.
											



										Executive Vice President - Product Development










												I. B.
											



										Senior Vice President - Corporate Development










												L. S.
											



										Vice President, Vaccine Research










												R. K.
											



										M.D; Vice President Clinical Development










												J. B.
											



										Chief Financial Officer, Senior Vice President, Secretary; Senior Vice President Chief Financial Officer and &#8230;










												S. P.
											



										Vice President Purchasing










												E. D.
											



										Director-Engineering










												L. S.
											



										Executive Director for Oncology Clinical Operations










												R. T.
											



										Associate Director, Quality Control










												S. S.
											



										Executive Director Pharmaceutical Sciences










												L. S.
											



										Associate Director, Project Planning and Management










												K. H.
											



										Manager










												D. M.
											



										Quality Assurance Specialist










												H. B.
											



										Manager










												G. C.
											



										Senior Director Quality Assurance










												J. C.
											



										Clinical Research Associate










												J. M.
											



										Manager










												S. D.
											



										Manager










												R. K.
											



										Manager










												T. R.
											



										Controller










												C. F.
											



										Manager










												S. R.
											



										Manager










												W. W.
											



										EH and S Manager










												G. P.
											



										Financial Compliance Manager










												J. M.
											



										Quality Control










												T. M.
											



										Research Scientist










												M. S.
											



										Associate Director Regulatory Affairs










												M. W.
											



										Research Manager










												D. B.
											



										Manager










												A. C.
											



										Manager










												C. B.
											



										Inventory










												M. S.
											



										Clinical Research










												. R.
											



										Account Manager










												S. B.
											



										Information Technology Staff










												J. D.
											



										Manager










												R. B.
											



										Associate Manager










												J. B.
											



										Finance










												D. M.
											



										Mammen Jr.










												P. A.
											



										Lalor









Activities



                Activities


 Producer
 Distributor
 Service provider



 Honey products

 Propolis



Barbiturates, sulphonamides, glycosides, alkaloids and antibiotics

Carbohydrates, proteins and enzymes

 Coenzyme Q10



 Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics

 Anaesthetics, basal

 Anaesthetics, inhalation

 Anaesthetics, intravenous (IV)

 Anaesthetics, spinal

 Anaesthetics, local

 Anaesthetic ether

 Anaesthetic chloroform

 Analeptics

 Analgesics

 Anti-Alzheimer agents

 Anticholinergics

 Anticonvulsants

 Anti-epileptics

 Anti-inflammatory preparations/anti-phlogistics

 Anti-inflammatories, non-steroidal

 Anti-neuralgics

 Anti-Parkinson agents

 Antipyretics

 Anti-arthritics

 Anti-rheumatic preparations

 Hematoporphyrin and preparations

 Stimulants and anti-depressive agents for the central nervous system

 Hypnotics, opiates

 Sedatives and tranquillisers

 Psychotropic products

 Muscle relaxants and their antagonists

 Phenylisopropylamine and salts (amphetamine)

 Sympatholytics

 Parasympathomimetics

 Sympathomimetics

 Calcium antagonists

 Neurological preparations



 Pharmaceutical preparations for the cardiovascular system

 Blood coagulants and haemostatics

 Anticoagulants for blood

 Antithrombins

 Blood decompressants

 Haemopoietics

 Cardioaccelerators

 Cardioregulators, pharmaceutical

 Cardiovascular products

 Cardiotonics

 Anti-arrhythmic preparations

 Angiotonics

 Coronary vasodilators

 Peripheral vasodilators

 Anti-varicose preparations

 Hypertensive agents

 Hypotensive agents



 Pharmaceutical preparations for ear, nose and throat (ENT) and dentistry

 Aural preparations

 Oropharyngeal preparations

 Nasopharyngeal preparations

 Nasal creams

 Nasal sprays

 Throat sprays

 Mouthwashes and throat washes, pharmaceutical

 Dental preparations



 Pharmaceutical preparations for ophthalmology

 Eye ointments

 Eye-drops, collyriums, pharmaceutical

 Ophthalmic preparations, mydriatic

 Eyewashes, pharmaceutical

 Steroid preparations for ophthalmic use

 Ophthalmic preparations NES



 Pharmaceutical preparations for metabolism, nutrition, alimentary systems

 Anti-dismetabolics

 Anti-obesity preparations, anorectics

 Anti-anaemics

 Bile and bile salt preparations

 Cholesterol reducing agents

 Appetite stimulants

 Foods and nutrients

 Herbal extracts, dietary

 Eutrophics

 Pharmaceutical preparations for metabolism NES

 Anti-diabetic pharmaceuticals

 Anabolic agents

 Ferritin

 Iron preparations, medical



 Pharmaceutical preparations for dermatology

 Dermatological fungicides and keratolytics

 Dermatological ointments and shampoos

 Dermatological sedatives, local

 Keratolytics

 Dermatological stimulants

 Antipruritics

 Calamine lotion

 Creams, nappy rash prevention

 Anti-acne preparations

 Steroid preparations for dermatological use

 Antipsoriatics

 Anti-burn preparations

 Creams, chilblain prevention

 Lip balm, lipsalve, medicated

 Wart removing preparations

 Corn removing preparations



 Pharmaceutical preparations for urology, gynaecology and obstetrics

 Contraceptive agents, chemical

 Galactagogues, galactophores

 Milk secretion stimulants, pharmaceutical

 Emmenagogues

 Vaginal preparations NES

 Pharmaceuticals, gynaecological and obstetrical, NES

 Diuretics, anti-diuretics

 Anti-enuretics

 Anti-urics

 Uricosuric agents

 Pharmaceuticals for urinary tract disorders NES

 Pharmaceuticals for renal disorders

 Anti-prostatics

 Erectile dysfunction drugs



 Pharmaceutical preparations for pneumology

 Catarrh preparations

 Cough syrups

 Respiratory stimulants

 Asthma preparations

 Cigarettes, medical, for asthmatics

 Bronchodilators



Chemotherapeutic preparations

 Gastroenterology and hepatology preparations

 Antacids and preparations for gastric ulcers

 Anti-diarrhoeal preparations

 Carminatives

 Cholagogues, choleretics, hepatoprotectors

 Hepatic products

 Laxatives and purgatives

 Laxatives, fig based

 Digestives (eupeptics), stomachics

 Emetics

 Anti-emetics and anti-nauseants

 Enema fluids

 Anti-lithiasis products

 Omeprazole

 Pharmaceuticals for gastrointestinal disorders NES



Immunological preparations

 Antiseptics and antibacterial preparations

 Skin and wound disinfectants

 Surgical spirit



 Pharmaceutical preparations NES

 Biopharmaceuticals

 Pharmaceutical preparations, vegetable based

 Pharmaceutical preparations, generic

 Radiopharmaceutical products

 Electrode creams and gels

 Diaphoretics

 Anti-allergic preparations and antihistamines

 Anhidrotics

 Allergens for diagnostic and desensitisation purposes

 Diagnostic kits, medical, biochemical

 Diagnostic aids and tests NES

 Surgical glue

 Haemostatic sponges, collagen

 Oils and liquid paraffin for pharmaceuticals

 Fish oils and fish oil extracts for medical use

 Colourants, edible, for pharmaceuticals

 Flavourings for pharmaceuticals

 Emulsifying agents for pharmaceuticals

 Solvents for pharmaceuticals

 Balsams, natural and synthetic, for pharmaceuticals

 Petrolatum/petroleum jelly, Vaseline for pharmaceuticals

 Pharmaceutical excipients

 Electrolytes, intravenous (IV) application

 Plasma substitutes

 Dialysis fluids

 Ointment bases for pharmaceuticals

 Coal tar bases, antiseptic and disinfectant

 Glucose solution, pharmaceutical

 Infusion solutions, subcutaneous and intravenous (IV)

 Solutions for haemodialysis

 Capsules, gelatine, for pharmaceuticals

 Capsules, soft, vegetable starch based, for pharmaceuticals

 Collodions for pharmaceutical use

 Sequestering agents for pharmaceuticals

 Microcrystalline cellulose for pharmaceuticals

 Cinchophen

 Guaiaphenesin

 Chondroitin sulphate

 Capsules, methylcellulose, for pharmaceuticals

 Plasters, medical, liquid

 Medicinal pastilles and lozenges

 Emulsions, pharmaceutical

 Oils, medicated

 Powders, medicated

 Tablets, effervescent, pharmaceutical, to customer specification



 Parapharmaceutical preparations

 Cough preparations, parapharmaceutical

 Inhalants, parapharmaceutical

 Blood tonics, parapharmaceutical

 Nerve tonics, parapharmaceutical

 Melissa cordials

 Tonic preparations for sportsmen

 Depuratives, parapharmaceutical

 Cod liver oil and halibut oil preparations

 Salt tablets, medicinal

 Nicotine replacement therapy products

 Anti-travel sickness tablets

 Haemorrhoidal preparations

 Slimming preparations, parapharmaceutical

 Cicatrizants

 Liniments, embrocations

 Emollients, parapharmaceutical

 Medicated pencils or sticks

 Insect repellents, parapharmaceutical

 Insect-bite lotions

 Jellyfish repellents, parapharmaceutical

 Tinctures, pharmaceutical

 Poultices

 Mud bath preparations

 Earplugs, wax

 Solvents, adhesive plaster removing

 Solutions, contact lens cleaning

 Shark cartilage products, parapharmaceutical

 Dietary supplements, mineral or vitamin based

 Parapharmaceutical products, Dead Sea minerals based

 Aromatherapy preparations

 Herb or grain filled cushions

 Herbal preparations, medicinal herbs and infusions

 Homeopathic preparations

 Emu oil products, parapharmaceutical



 Gynaecological and obstetrical equipment

 Test kits, pregnancy



Textile articles for medical and surgical use

Research, general







                Other classifications (for some countries)



SIC (US 1987) : 
Biological products, except diagnostic substances (2836)
NAICS (US 2012) : 
Biological Product (except Diagnostic) Manufacturing (325414)










You might also like



















     Contact

            Vical Inc





Call
Click to see their phone number








Call
Click to see their phone number















---




						Service 
						
						+ call price





* This phone number available for 3 min is not the recipient's number but a number from a service which will put you through to that person.
				This service is produced by Kompass. 
                					Why this number ?
















Service & free calls*






* This number, only available 3 minutes, is not your correspondant's number but the number of a service putting you through to that person.
This service is produced by Kompass. 
									Why this number ?










All the lines are busy at the moment, please try again in a moment.











You might also like:












Suneva Medical Inc


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Botanical Laboratories


                                                         
                                                        Ferndale
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Isis Pharmaceuticals Inc


                                                         
                                                        Carlsbad
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Corvas International, Inc


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Bio Cryst Pharmaceuticals...


                                                         
                                                        Hoover
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Neurocrine Biosciences In...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Ligand Pharmaceuticals In...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Hollis-Eden Pharmaceutica...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Imagenetix Inc New


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Anadys Pharmaceuticals In...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Axonyx Inc


                                                         
                                                        La Jolla
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Favrille Inc


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Immune Response Corp


                                                         
                                                        Carlsbad
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Mckenna Labs, Inc.


                                                         
                                                        SAN DIEGO
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Scweizerhall Greenville


                                                         
                                                        Greenville
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












ADP


                                                         
                                                        Birmingham
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Alliance Pharmaceutical C...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Vyrex Corp


                                                         
                                                        La Jolla
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics
















Illumina Inc


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics












Protein Polymer Technolog...


                                                         
                                                        San Diego
Pharmaceutical preparations for the central and autonomic nervous system and anaesthetics







 
 




Our business solutions









With Kompass :




                            Global presence in more than 60 countries





                            Detailed and up to date company information





                            Comprehensive and filtered company directory


















				                Frequent updates ensuring high quality data






                                    Secure online payment






                                Help with expert advice






    	            			Dedicated customer service team













Contact Kompass North America




Contact us





















































	Vical - Investors - Stock Information












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04















Investors














Overview





Stock Information





News Releases






Events & Presentations






SEC Filings










OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings









Home / Investors / Stock Information









Stock Quote (NASDAQ GM)









NASD : VICL



Stock Quote: NASD




Price
2.58


Change
-0.04




Volume
41,560


% Change
-1.53%




Intraday High
2.69


52 Week High
4.50




Intraday Low
2.58


52 Week Low
2.05




Today's Open
2.59


Previous Close
2.62



July 28, 2017 03:59 PM Pricing delayed 20 minutes









Historical Stock Quote



Lookup Date  
				
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

				  
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

				  
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
  
				






High
2.69
Low
2.53


Volume
175,200
Opening Price
2.64




Last
2.62






No Data Returned for

- Please select another date







CONNECT WITH US



RSS Feeds 
Email Alerts 
LinkedIn 
Slideshare 
StockTwits 
Twitter 
YouTube




IRS Form 8937














About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    















	Vical - Products - Pipeline












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04











Products














Pipeline





ASP0113 Therapeutic CMV Vaccine





CyMVectin™ Prophylactic CMV Vaccine





VCL-HB01 Therapeutic HSV-2 Vaccine





VL-2397 Antifungal





Other Products






Apex®-IHN





Dengue Vaccine





ONCEPT®










PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalApex®-IHNDengue VaccineONCEPT®Other Products









Home / Products / Pipeline










 











About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    













	Vical - About Us - Management












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04













About Us














Overview





Corporate Governance





Board of Directors






Board Committees






Management





Careers









OverviewCorporate GovernanceBoard CommitteesBoard of DirectorsManagementCareers









Home / About Us / Management








Management




Vijay B.  Samant, President and Chief Executive Officer




Vijay B. Samant joined us as President and Chief Executive Officer in November 2000. Mr. Samant has 23 years of diverse U.S. and international sales, marketing, operations, and business development experience with Merck. From 1998 to mid-2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs, and Executive Director of Materials Management. Mr. Samant earned a master's degree in management studies from the Sloan School of Management at the Massachusetts Institute of Technology in 1983. He received a master's degree in chemical engineering from Columbia University in 1977 and a bachelor's degree in chemical engineering from the University of Bombay, University Department of Chemical Technology, in 1975. Mr. Samant presently serves as a member of the board of directors of AmpliPhi Biosciences Corporation. Mr. Samant was a member of the Board of Directors for Raptor Pharmaceutical from 2011 to 2014, and was a member of the Board of Directors for BioMarin Pharmaceutical from 2002 to 2004. Mr. Samant was a Director of the Aeras Global TB Vaccine Foundation (Rockville, MD) from 2001 to 2010; a member of the Board of Trustees for the National Foundation for Infectious Diseases (NFID, Bethesda, MD) from 2003 to 2012; and a member of the Board of Trustees for the International Vaccine Institute (IVI, Seoul, Korea) from 2008 to 2012.








Mammen P. "Anza" Mammen, Jr., M.D., Senior Vice President, Clinical Development




Mammen P. “Anza” Mammen, Jr., M.D., joined us as Vice President, Clinical Vaccines in November 2012 and was named Senior Vice President, Clinical Development in May 2017. Prior to joining Vical, Dr. Mammen retired as a colonel after a 21-year career in the Army Medical Corps, most recently as Infectious Disease Consultant and Chief, Pandemic Warning Team, U.S. Department of Defense. From 2006 to 2010, he served as the Army’s Product Manager for vaccines in Advanced Development against dengue, hepatitis E, and HIV viruses for the U.S. Army Medical Research and Materiel Command (USAMRMC). He was Chief, Department of Virology, the Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand, from 2001 to 2006 when he managed U.S. Food and Drug Administration-regulated vaccine field studies. His previous assignments include serving as Infectious Disease Officer, Walter Reed Army Institute of Research (WRAIR), and Chief, Internal Medicine Clinic, 121st General Hospital, Seoul, South Korea. Dr. Mammen received his M.D. degree from the Pennsylvania State University College of Medicine and is Board-certified in Infectious Diseases. He has been elected as Fellow by the Infectious Disease Society of America (IDSA) and the American College of Physicians (ACP). He received his Internal Medicine and Infectious Disease clinical training from the Walter Reed Army Medical Center. He earned a B.A. degree in mathematics from Williams College.








Larry R.  Smith, Ph.D., Senior Vice President, Research




Larry R. Smith, Ph.D., joined us as Executive Director, Vaccinology in September 2003, and was named Senior Vice President, Research in May 2017. Dr. Smith was Director of Viral Vaccines Research at Wyeth Vaccines, where he oversaw the immunogenicity testing of various viral vaccines including a number of recombinant viral vectors. Prior to joining Wyeth in 1996, Dr. Smith was a Scientific Investigator at Immune Response Corporation, where he identified autoreactive T cell targets in psoriasis and multiple sclerosis which led to the clinical testing of several therapeutic vaccine candidates. Dr. Smith received a B.S. degree in Biology from Purdue University, a Ph.D. in Microbiology and Immunology from the University of Texas Medical Branch, and was a postdoctoral fellow in the Immunology Department at Scripps Clinic and Research Foundation.








Anthony A. Ramos, Chief Financial Officer




Anthony A. Ramos joined us as Corporate Controller in February 2005 and was named Chief Financial Officer in May 2017. From January 1999 until joining Vical, Mr. Ramos held various positions at Copper Mountain Networks, Inc., a publicly held network communications company, most recently as Vice President of Finance with broad responsibilities in finance, accounting, treasury, risk management and corporate governance. From April 1996 until joining Copper Mountain Networks, Inc., Mr. Ramos was Accounting Manager at Viasat, Inc., a publicly held digital communications company, where he held accounting and financial reporting responsibilities. From January 1990 until joining Viasat, Inc., Mr. Ramos served as an audit manager at PricewaterhouseCoopers LLP, where his clients included life sciences, computer software and telecommunications companies as well as government contractors. Mr. Ramos received his bachelor’s degree in business administration and accounting from San Diego State University and is a Certified Public Accountant.








Keith D. Hall, Vice President, Operations




Keith D. Hall joined us as Director Quality Control and Assay Development in February 2003 and was named Vice President, Operations in April 2016. Mr. Hall has 28 years of biopharmaceutical experience including manufacturing, process development, assay development, and quality. From 2000 to 2003 he served as Director of Manufacturing for Agennix in Houston, TX where he oversaw drug substance and product manufacture, and the design, construction and commissioning of a recombinant human lactoferrin bulk drug substance manufacturing facility in Italy. From 1994 to 2000 he served as Senior Manager, Quality Control and Analytical Development for Valentis/GeneMedicine in The Woodlands, TX. Prior to 1994, Mr. Hall served in various development and manufacturing positions of increasing responsibilities at Hybritech and Amgen.  He earned a master’s degree in business administration from the C.T. Bauer College of Business at the University of Houston, and a bachelor’s degree in microbiology from the University of California at Santa Barbara.

















About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    













	Vical - Technology - Publications












































About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers








 


NASDAQ | VICL:
2.58

 -0.04













Technology














DNA Technology






Poloxamer Delivery System






Vaxfectin® Adjuvant





Publications









Poloxamer Delivery SystemDNA TechnologyVaxfectin® AdjuvantPublications









Home / Technology / Publications









Publications


2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1987
 

2014

Bilinsky IP and Smith LR. Questionnaire for Biotechs: Vical Incorporated. Hum Vaccin Immunother. 2014 Dec;10(10):2783-4. Doi: 10.4161/21645515.2014.988013.

2013

Smith LR, et al. Clinical development of a cytomegalovirus DNA vaccine: From product concept to pivotal phase 3 trial. Vaccines. 2013 Sep;1(4):398-414. Doi: 10.3390/vaccines1040398.
Kulkarni V, et al. Vaccination with Vaxfectin adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 viremia. Hum Vaccin Immunother. 2013 Jul 2;9(10):2069-2080. Doi: 10.4161/hv.25442.
Bilinsky IP and Smith LR. Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines. Hum Vaccin Immunother. 2013 Jun 9;9(6):1333-1345. Doi: 10.4161/hv.24209.
Lin WH, et al. Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins. J Virol 2013 Jun;87(12):6560-8. doi: 10.1128/JVI.00635-13..
Chuang I,  et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013 Feb 14;8(2):e55571. doi: 10.1371/journal.pone.0055571..
Kharfan-Dabaja MA,  et al. Reanalysis of TransVax immunogenicity. Lancet Infect Dis 2013 Jan;13(1):18. doi: 10.1016/S1473-3099(12)70296-7.

2012

Raviprakash K, et al. A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum Vaccin Immunother 2012 Dec 1;8(12):1764-8. doi: 10.4161/hv.21806. Epub 2012 Oct 2.
Doukas J, Rolland A. Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther 2012 Dec;19(12):811-7. doi: 10.1038/cgt.2012.69. Epub 2012 Oct 5. Review.
Hartikka J,  et al. Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus. Hum Vaccin Immunother 2012 Nov 1;8(11):1595-606. doi: 10.4161/hv.21225. Epub 2012 Aug 24.
Richie TL,  et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Immunotherapy 2012 Nov 1; 8(11):1564-84. doi: 10.4161/hv.22129. Epub 2012 Nov 1.
Veselenak RL,  et al. A Vaxfectin®-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 2012 Nov 19;30 (49):7046-51. doi: 10.1016/j.vaccine.2012.09.057. Epub 2012 Oct 4.
Shlapobersky M, et al. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 2012 Jun;93(Pt 6):1305-15. doi: 10.1099/vir.0.040055-0. Epub 2012 Mar 7.
Kharfan-Dabaja MA,  et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012 Apr;12(4):290-9. doi: 10.1016/S1473-3099(11)70344-9. Epub 2012 Jan 10. Erratum in: Lancet Infect Dis. 2012 Apr;12(4):266.

2011

Doukas J, et al. Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®. Vaccine 2011 Jul 26;29(33):5443-52. doi: 10.1016/j.vaccine.2011.05.060. Epub 2011 Jun 17.
Ledgerwood J, et al. A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. J Infect Dis 2011 203 1396-404.
Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: Allovectin-7®. Immunotherapy 2011;3 17-21.

2010

Sullivan S et al. Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines. Expert Opin Drug Del 2010 7 1433-1446.
Bedikian AY et al. A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res 2010 20 218-226.
Sedegah M et al. Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine 2010; 28 3055-3065.
Smith LR et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010; 28 2565-2572.
Soares HP, Lutzky J; Velimogene aliplasmid. Exp Opin Biol Ther 2010; 10 841-851.

2009

Hartikka J et al. Vaxfectin®, a cationic lipid-based adjuvant for protein-based influenza vaccines. Vaccine 2009; 27 6399-6403.
Moss RB. Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Imm Based Ther Vacc 2009; 7 3.
Muller WJ et al. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J Gen Virol 2009; 90 1153-1163.
Schleiss M. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther 2009; 11 572-578.
Shlapobersky M et al. Vaxfectin®-adjuvanted seasonal influenza protein vaccine: correlation of systemic and local immunological markers with formulation parameters. Vaccine 2009; 27 6404-6410.
Vilalta A et al. Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA. Vaccine 2009; 27 7409-7417.
Ye M et al. Rapid development of a Vaxfectin®-adjuvanted DNA vaccine encoding pandemic swine-origin influenza A virus (H1N1) hemagglutinin. Gene Ther Reg 2009; 4 45-55.

2008

Bedikian AY, Del Vecchio M. Allovectin-7 therapy in metastatic melanoma. Exp Opin Biol Ther 2008; 8 839-844.
Dery M, Bausch DG. A DNA vaccine for the prevention of Ebola virus infection. Curr Opin Mol Ther 2008; 10 285-293.
Go V, Pollard RB. A Cytomegalovirus Vaccine for Transplantation: Are We Closer? J Infect Dis 2008; 197 1631-3.
Hartikka J et al. Physical characterization and in vivo evaluation of poloxamer-based DNA vaccine formulations. J Gene Med 2008; 10 770-782.
Horton H, Lalor P, Rolland A. IL-2 plasmid electroporation: from preclinical studies to phase I clinical trial. Methods Mol Biol 2008; 423 361-372.
Lalor PA et al. Plasmid DNA-Based Vaccines Protect Mice and Ferrets against Lethal Challenge with A/Vietnam/1203/04 (H5N1) Influenza Virus. J Infect Dis 2008; 197 1643-52.
Mahajan R et al. A TaqMan® Reverse Transcription Polymerase Chain Reaction (RT-PCR) In Vitro Potency Assay for Plasmid-based Vaccine Products. Mol Biotechnol 2008; 40 47-57.
Martin JE et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008; 26 6338-6343.
Pan CH et al. Use of Vaxfectin adjuvant with DNA vaccine encoding the measles virus hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques against measles virus. Clin Vaccine Immunol 2008; 15 1214-1221.
Wloch MK et al. Safety and Immunogenicity of a Bivalent Cytomegalovirus DNA Vaccine in Healthy Adult Subjects. J Infect Dis 2008; 197 1634-42.

2007

Abai AM et al. Novel microneutralization assay for HCMV using automated data collection and analysis. J Immunol Methods 2007; 322 82-93.
Jiang G et al. Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization. Malar J 2007; 6 135.
Jimenez GS et al. Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin 2007; 3 157-164.
Kaslow DC. Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter. Hum Vaccin 2007; 3 1-7.
Martin JE et al. A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial.  J Infect Dis 2007; 196 1732-1740.
Sandbulte MR et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007; 4 e59.
Selinsky C et al. Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human IgG antibodies to anthrax lethal factor antigen. Biologicals 2007; 35 123-129.
Tompkins SM et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13 426-435.
Vilalta A et al. Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge. Hum Gene Ther 2007; 18 763-771.

2006

Dunachie SJ et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006; 74 5933-5942.
Gonzalez R et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16 521-526.
Hahn UK, Aichler M, Boehm R, Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 2006; 24 4595-4597.
Leamy VL et al. Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines. Hum Vaccin 2006; 2 113-118.
Margalith M, Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 2006; 4 2.
Minke JM et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol 2006; 111 47-57.
Rolland A. Nuclear gene delivery: the Trojan horse approach. Expert Opin Drug Deliv 2006; 3 1-10.
Romano M et al. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 2006; 24 3353-3364.
Sedegah M et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24 1921-1927.

2005

Hirsch-Lerner D et al. Effect of "helper lipid" on lipoplex electrostatics. Biochim Biophys Acta 2005; 1714 71-84.
Manthorpe M et al. Plasmid vaccines and therapeutics: from design to applications. Adv Biochem Eng Biotechnol 2005; 99 41-92.
Rolland A. Gene medicines: the end of the beginning? Adv Drug Deliv Rev 2005; 57 669-673.
Selinsky C et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccin 2005; 1 16-23.
Vilalta A et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum Gene Ther 2005; 16 1143-1150.
Vilalta A et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum Gene Ther 2005; 16 1151-1156.
Yanagie H, Eriguchi M. [Gene therapy for liver metastasis of colon cancer]. Nippon Rinsho 2005; 63 Suppl 12 537-543.

2004

Arpicco S et al. Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids. Farmaco 2004; 59 869-878.
Evans TG et al. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines. Vaccine 2004; 22 2626-2630.
Ferrari ME, Hermanson G, Rolland A. Development of anthrax DNA vaccines. Curr Opin Mol Ther 2004; 6 506-512.
Galanis E et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 2004; 101 2557-2566.
Geall AJ et al. Targeting malaria with polyamines. Bioconjug Chem 2004; 15 1161-1165.
Hermanson G et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004; 101 13601-13606.
Kaslow DC. A potential disruptive technology in vaccine development: gene-based vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 2004; 98 593-601.
Li J et al. The immunoregulation of mice by somatic transgenic expression of porcine interleukin-6 gene and CpG sequence. Vet Res Commun 2004; 28 33-46.
Li X et al. [Modulation of immune response to Plasmodium falciparum apical membrane antigen 1 DNA vaccine by cytokine plasmids]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2004; 22 136-138.
Locher CP, Witt SA, Ashlock BM, Levy JA. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol 2004; 23 107-110.

2003

Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7®) in patients with metastatic melanoma. Expert Opin Biol Ther 2003; 3 377-384.
Coker C, Majid M, Radulovic S. Development of Rickettsia prowazekii DNA vaccine: cloning strategies. Ann N Y Acad Sci 2003; 990 757-764.
Dai B et al. [Analysis of CpG motifs in endoflagellar gene (flaB2) and expression vector (VR1012) of leptospiral DNA vaccine]. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34 1-4.
Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM. DNA vaccines induce partial protection against Leishmania mexicana. Vaccine 2003; 21 2161-2168.
Fischer L et al. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 2003; 21 4593-4596.
Fischer L et al. Vaccination of puppies with a lipid-formulated plasmid vaccine protects against a severe canine distemper virus challenge. Vaccine 2003; 21 1099-1102.
Glazyrin AL, Kan-Mitchell J, Mitchell ML. Analysis of in vitro immunization: generation of cytotoxic T-lymphocytes against allogeneic melanoma cells with tumor lysate-loaded or tumor RNA-transfected antigen-presenting cells. Cancer Immunol Immunother 2003; 52 171-178.
Hellum M et al. Photochemically enhanced gene delivery with cationic lipid formulations. Photochem Photobiol Sci 2003; 2 407-411.
Nukuzuma C, Ajiro N, Wheeler CJ, Konishi E. Enhancing effect of Vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol 2003; 16 183-189.
Rainczuk A, Scorza T, Smooker PM, Spithill TW. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors. Infect Immun 2003; 71 4506-4515.
Rainczuk A et al. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol. Vaccine 2003; 21 3030-3042.
Rath A et al. Characterization of immune response in mice to plasmid DNA encoding dog zona pellucida glycoprotein-3. Vaccine 2003; 21 1913-1923.

2002

D'Souza S et al. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70 3681-3688.
Ferrari ME, Rusalov D, Enas J, Wheeler CJ. Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes. Nucleic Acids Res 2002; 30 1808-1816.
Galanis E. Technology evaluation: Allovectin-7, Vical. Curr Opin Mol Ther 2002; 4 80-87.
Gaucheron J, Santaella C, Vierling P. Transfection with fluorinated lipoplexes based on fluorinated analogues of DOTMA, DMRIE and DPPES. Biochim Biophys Acta 2002; 1564 349-358.
Hogset A et al. Photochemical transfection: a technology for efficient light-directed gene delivery. Somat Cell Mol Genet 2002; 27 97-113.
Hong YS et al. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002; 21 1188-1200.
Kaslow DC. Transmission-blocking vaccines. Chem Immunol 2002; 80 287-307.
Ota T, Maeda M, Tatsuka M. Cationic liposomes with plasmid DNA influence cancer metastatic capability. Anticancer Res 2002; 22 4049-4052.
Prasmickaite L, Hogset A, Berg K. The role of the cell cycle on the efficiency of photochemical gene transfection. Biochim Biophys Acta 2002; 1570 210-218.
Rath A et al. Antibodies generated in response to plasmid DNA encoding zona pellucida glycoprotein-B inhibit in vitro human sperm-egg binding. Mol Reprod Dev 2002; 62 525-533.
Sankar V et al. Salivary gland delivery of pDNA-cationic lipoplexes elicits systemic immune responses. Oral Dis 2002; 8 275-281.
Seki M, Iwakawa J, Cheng H, Cheng PW. p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Hum Gene Ther 2002; 13 761-773.
Singh G, Parker S, Hobart P. The development of a bicistronic plasmid DNA vaccine for B-cell lymphoma. Vaccine 2002; 20 1400-1411.
Timmerman JM et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002; 62 5845-5852.
Uchida E, Mizuguchi H, Ishii-Watabe A, Hayakawa T. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002; 25 891-897.
Vellon L et al. Enhanced uptake of antisense oligonucleotides using cationic liposomes and the apoptotic effect of idarubicin in K-562 cell line. Leuk Res 2002; 26 669-676.
Vilalta A, Whitlow V, Martin T. Real-time PCR determination of Escherichia coli genomic DNA contamination in plasmid preparations. Anal Biochem 2002; 301 151-153.
Zhang T, Tsang TC, Harris DT. Comparison of cis and trans tat gene expression in HIV LTR-based amplifier vectors. Biotechniques 2002; 33 1146-1151.

2001

Baccaglini L et al. Cationic liposome-mediated gene transfer to rat salivary epithelial cells in vitro and in vivo. J Gene Med 2001; 3 82-90.
Belldegrun A et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001; 12 883-892.
Daniels GA, Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther 2001; 3 70-76.
Ferrari ME, Rusalov D, Enas J, Wheeler CJ. Trends in lipoplex physical properties dependent on cationic lipid structure, vehicle and complexation procedure do not correlate with biological activity. Nucleic Acids Res 2001; 29 1539-1548.
Fleeton MN et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001; 183 1395-1398.
Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. J Control Release 2001; 73 401-416.
Gleich LL et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001; 127 775-779.
Hartikka J et al. Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. Mol Ther 2001; 4 407-415.
Hartikka J et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001; 19 1911-1923.
Kaiser S, Toborek M. Liposome-mediated high-efficiency transfection of human endothelial cells. J Vasc Res 2001; 38 133-143.
Kaushik A. Leuvectin Vical Inc. Curr Opin Investig Drugs 2001; 2 976-981.
Madry H, Reszka R, Bohlender J, Wagner J. Efficacy of cationic liposome-mediated gene transfer to mesangial cells in vitro and in vivo. J Mol Med 2001; 79 184-189.
Parker SE et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001; 8 1011-1023.
Pleyer U et al. Efficiency and toxicity of liposome-mediated gene transfer to corneal endothelial cells. Exp Eye Res 2001; 73 1-7.
Pupa SM et al. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther 2001; 8 75-79.
Reyes L et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 2001; 19 3778-3786.
Sanchez GI et al. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infect Immun 2001; 69 3897-3905.
Schleef RR, Olman MA, Miles LA, Chuang JL. Modulating the fibrinolytic system of peripheral blood mononuclear cells with adenovirus. Hum Gene Ther 2001; 12 439-445.
Scholl FG et al. Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis. J Heart Lung Transplant 2001; 20 322-329.
Simberg D et al. Phase behavior, DNA ordering, and size instability of cationic lipoplexes. Relevance to optimal transfection activity. J Biol Chem 2001; 276 47453-47459.
Stopeck AT et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7 2285-2291.
Suzuki S et al. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Urol Int 2001; 67 216-223.
Ushijima K et al. Anti-HIV-1 activity of an antisense phosphorothioate oligonucleotide bearing imidazole and primary amine groups. Bioorg Med Chem 2001; 9 2165-2169.
Vilalta A, Wu D, Margalith M, Hobart P. Rabbit EPO gene and cDNA: expression of rabbit EPO after intramuscular injection of pDNA. Biochem Biophys Res Commun 2001; 284 823-827.
Yonezawa T et al. Detection of transgene in progeny at different developmental stages following testis-mediated gene transfer. Mol Reprod Dev 2001; 60 196-201.

2000

Abul-Hassan K, Walmsley R, Boulton M. Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells. Curr Eye Res 2000; 20 361-366.
Aujame L, Seguin D, Droy C, Hessler C. Experimental design optimization of filamentous phage transfection into mammalian cells by cationic lipids. Biotechniques 2000; 28 1202-1206, 1208, 1210 passim.
Blanton JR, Jr. et al. Plasmid transfection and retroviral transduction of porcine muscle cells for cell-mediated gene transfer. J Anim Sci 2000; 78 909-918.
Clark PR, Stopeck AT, Parker SE, Hersh EM. Cationic lipid gene transfer of an IL-2 transgene leads to activation of natural killer cells in a SCID mouse human tumor xenograft. Cell Immunol 2000; 204 96-104.
Clark PR et al. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA. Cancer Gene Ther 2000; 7 853-860.
Clayton J, Middlebrook JL. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000; 18 1855-1862.
Dai B et al. Protection against leptospirosis by immunization with plasmid DNA encoding 33 kDa endoflagellin of L. interrogans serovar Lai. Chin Med Sci J 2000; 15 14-19.
Dassow H, Lassner D, Remke H, Preiss R. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules. Int J Clin Pharmacol Ther 2000; 38 209-216.
Dumonteil E et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana. Dev Biol (Basel) 2000; 104 135-141.
Gleich LL. Gene therapy for head and neck cancer. Laryngoscope 2000; 110 708-726.
Gutheil JC. Novel immunologic and biologic therapies for breast cancer. Curr Oncol Rep 2000; 2 582-586.
Gutheil JC et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6 3056-3061.
Hartikka J et al. Sodium phosphate enhances plasmid DNA expression in vivo. Gene Ther 2000; 7 1171-1182.
Hoffman DM, Figlin RA. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol 2000; 18 152-156.
Horiguchi Y et al. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther 2000; 7 844-851.
Kunitomi M et al. Selective inhibition of hepatoma cells using diphtheria toxin A under the control of the promoter/enhancer region of the human alpha-fetoprotein gene. Jpn J Cancer Res 2000; 91 343-350.
Larchian WA et al. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin Cancer Res 2000; 6 2913-2920.
Le TP et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000; 18 1893-1901.
Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. Gene Ther 2000; 7 286-291.
Mizuta T et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. Biochem Biophys Res Commun 2000; 279 158-161.
Norman JA et al. DNA vaccine encoding PSMA significantly reduces tumor growth and prolongs life in mice with TRAMP tumors. Clinical Cancer Research 2000; 6 511.
Sedegah M et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000; 164 5905-5912.
Takagi T et al. Effect of cationic liposomes on intracellular trafficking and efficacy of antisense oligonucleotides in mouse peritoneal macrophages. J Drug Target 2000; 7 363-371.
Thompson JA et al. Phase II trial of plasmid DNA/lipid (leuvectin) immunotherapy in patients with metastatic renal cell carcinoma. Clinical Cancer Research 2000; 6 517.
Vellon L, Cuello T, Gargallo P, Larripa I. [Antisense oligonucleotides increase the apoptotic effect of idarubicin in K-562 cell line]. Medicina (B Aires) 2000; 60 143-145.
Zelphati O et al. PNA-dependent gene chemistry: stable coupling of peptides and oligonucleotides to plasmid DNA. Biotechniques 2000; 28 304-310, 312-304, 316.
Zhang YY et al. Immunogenicity of plasmid DNA encoding the 62 kDa fragment of Schistosoma japonicum myosin. Vaccine 2000; 18 2102-2109.

1999 

Abai AM, Hobart PM, Barnhart KM. Insulin delivery with plasmid DNA. Hum Gene Ther 1999; 10 2637-2649.
Abai AM, Hobart PM, Norman J. Gene therapy for type-1 diabetes. Diabetes 1999; 48 51.
Akporiaye ET, Hersh E. Clinical aspects of intratumoral gene therapy. Curr Opin Mol Ther 1999; 1 443-453.
Anderson KL et al. PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation. Blood 1999; 94 2310-2318.
Barnhart KM. Simplified PCR-mediated, linker-scanning mutagenesis. Biotechniques 1999; 26 624-626.
Cameron FH et al. A transfection compound series based on a versatile Tris linkage. Biochim Biophys Acta 1999; 1417 37-50.
Chang Y, Prud'homme GJ. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J Gene Med 1999; 1 415-423.
Clayman GL, Dreiling L. Local delivery for gene therapy. Curr Oncol Rep 1999; 1 138-143.
Fernandes J et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999; 154 1159-1169.
Figlin RA, Parker SE, Horton HM. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma. Curr Opin Mol Ther 1999; 1 271-278.
Galanis E et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17 3313-3323.
Hasan UA et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines. J Immunol Methods 1999; 229 1-22.
Hermanson GG, Singh G, Hobart P. Immunogenicity and protective effects of coadministered cytokine and chemokine plasmid DNAs in a murine B-cell lymphoma model. Cancer Gene Therapy 1999; 6 112.
Hernandez P, Hof R, Parker S, Horton H. Systemic treatment of cancer by intramuscular injection of an interferon-alpha-expressing plasmid DNA. Cancer Gene Therapy 1999; 6 108.
Hersh E et al. Long-term follow-up of melanoma patients who have received Allovectin-7 gene therapy treatment. Cancer Gene Therapy 1999; 6 92.
Horton HM, Hernandez P, Parker SE, Barnhart KM. Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice. Cancer Res 1999; 59 4064-4068.
Horton HM, Parker SE, Wloch MK, Norman JA. DNA vaccines for cancer therapy. Expert Opin Investig Drugs 1999; 8 2017-2026.
Horton HM et al. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha. Proc Natl Acad Sci USA 1999; 96 1553-1558.
Horton HM et al. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile. J Immunol 1999; 163 6378-6385.
Ilan Y. Technology evaluation: naked DNA. Curr Opin Mol Ther 1999; 1 116-120.
Kisich KO, Malone RW, Feldstein PA, Erickson KL. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment. J Immunol 1999; 163 2008-2016.
Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999; 162 254-262.
Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 1999; 17 19-25.
Li K, Stewart DJ, Ward HJ. Technology evaluation: gene therapy (FGF-5), Vical. Curr Opin Mol Ther 1999; 1 260-265.
Martin T et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999; 10 759-768.
Miao J et al. [Humoral immune response in mice to hybrid nucleic acid vaccines containing Plasmodium falciparum merozoite surface protein 1 block 17-based gene]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 1999; 17 302-304.
Neglia F et al. DNA vaccination against the ovarian carcinoma-associated antigen folate receptor alpha (FRalpha) induces cytotoxic T lymphocyte and antibody responses in mice. Cancer Gene Ther 1999; 6 349-357.
Ochiya T et al. Evaluation of cationic liposome suitable for gene transfer into pregnant animals. Biochem Biophys Res Commun 1999; 258 358-365.
Oku N. Delivery of contrast agents for positron emission tomography imaging by liposomes. Adv Drug Deliv Rev 1999; 37 53-61.
Pal S et al. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge. Vaccine 1999; 17 459-465.
Parker SE et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 1999; 10 741-758.
Pereira-Chioccola VL et al. Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein. Parasite Immunol 1999; 21 103-110.
Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999; 6 771-777.
Ramasamy R et al. Mammalian cell expression of malaria merozoite surface proteins and experimental DNA and RNA immunisation. Biochim Biophys Acta 1999; 1453 1-13.
Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999; 5 2766-2772.
Schreiber A et al. Effect of Leuvectin, an interleukin-2 gene therapy agent, on prostate-specific antigen (PSA) in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer. Cancer Gene Therapy 1999; 6 91.
Smith GJ, 3rd et al. Fast and accurate method for quantitating E. coli host-cell DNA contamination in plasmid DNA preparations. Biotechniques 1999; 26 518-522, 524, 526.
Smooker PM et al. Humoral responses in mice following vaccination with DNA encoding glutathione S-transferase of Fasciola hepatica: effects of mode of vaccination and the cellular compartment of antigen expression. Parasite Immunol 1999; 21 357-364.
Wloch MK et al. Human gp100 plasmid DNA vaccination induces cytotoxic T lymphocytes (CTLs) that lyse interferon-alpha (IFN-alpha)-treated but not untreated mouse melanoma cells. Cancer Gene Therapy 1999; 6 113.
You Z et al. [Immunogenicity and immunoprotection of a leptospiral DNA vaccine]. Hua Xi Yi Ke Da Xue Xue Bao 1999; 30 128-132.
Zelphati O, Liang XW, Hobart P, Felgner PL. Gene chemistry: Functionally and conformationally intact fluorescent plasmid DNA. Human Gene Therapy 1999; 10 15-24.

1998

Anchordoquy TJ, Girouard LG, Carpenter JF, Kroll DJ. Stability of lipid/DNA complexes during agitation and freeze-thawing. J Pharm Sci 1998; 87 1046-1051.
Barnhart KM et al. Enhancer and promoter chimeras in plasmids designed for intramuscular injection: a comparative in vivo and in vitro study. Hum Gene Ther 1998; 9 2545-2553.
Campain JA et al. Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi's sarcoma cell lines. Cancer Gene Ther 1998; 5 131-143.
DeBruyne LA et al. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther 1998; 5 1079-1087.
Doolan DL et al. DNA vaccination as an approach to malaria control: current status and strategies. Curr Top Microbiol Immunol 1998; 226 37-56.
Felgner PL, Rolland A. Preface. Adv Drug Deliv Rev 1998; 30 1-3.
Ferrari ME et al. Analytical methods for the characterization of cationic lipid-nucleic acid complexes. Hum Gene Ther 1998; 9 341-351.
Gleich LL et al. Alloantigen gene therapy for squamous cell carcinoma of the head and neck: results of a phase-1 trial. Arch Otolaryngol Head Neck Surg 1998; 124 1097-1104.
Hedstrom RC et al. In vitro expression and in vivo immunogenicity of Plasmodium falciparum pre-erythrocytic stage DNA vaccines. Int J Mol Med 1998; 2 29-38.
Hernandez P, Anderson D, Parker S, Horton H. A novel plasmid DNA gene therapy for treatment of metastatic disease. Cancer Gene Therapy 1998; 5 D11.
Horton HM et al. Development of a novel plasmid DNA gene therapy for treatment of distant primary and metastatic tumors in mice. Cancer Gene Therapy 1998; 5 28.
Huang CY et al. Lipitoids--novel cationic lipids for cellular delivery of plasmid DNA in vitro. Chem Biol 1998; 5 345-354.
Konopka K et al. Delivery of an anti-HIV-1 ribozyme into HIV-infected cells via cationic liposomes. Biochim Biophys Acta 1998; 1372 55-68.
Lahijani R et al. Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive polymerase chain reaction and enzyme-linked immunosorbent assay. Hum Gene Ther 1998; 9 1173-1180.
McCluskie MJ et al. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev 1998; 8 401-414.
Murphy JE et al. A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery. Proc Natl Acad Sci USA 1998; 95 1517-1522.
Nabel GJ, Hobart P. Keystone symposia on: molecular and cellular biology of gene therapy and synthetic non-viral gene delivery systems, Keystone, CO, USA, January 19-25, 1998. Biochim Biophys Acta 1998; 1378 R19-26.
Raghupathi R et al. BCL-2 overexpression attenuates cortical cell loss after traumatic brain injury in transgenic mice. Journal Of Cerebral Blood Flow And Metabolism 1998; 18 1259-1269.
Rolland A, Felgner PL. Non-viral gene delivery systems - Preface. Advanced Drug Delivery Reviews 1998; 30 1-3.
Saffran DC et al. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Cancer Gene Ther 1998; 5 321-330.
Sawai K et al. A novel method of cell-specific mRNA transfection. Mol Genet Metab 1998; 64 44-51.
Sedegah M et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998; 95 7648-7653.
Stopeck AT et al. Transfection of primary tumor cells and tumor cell lines with plasmid DNA/lipid complexes. Cancer Gene Ther 1998; 5 119-126.
Surovoy A, Flechsler I, Jung G. A novel series of serum-resistant lipoaminoacid compounds for cellular delivery of plasmid DNA. Adv Exp Med Biol 1998; 451 461-467.
Wang R et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282 476-480.
Wang R et al. Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun 1998; 66 4193-4202.
Weiss WR et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161 2325-2332.
Zelphati O et al. Stable and monodisperse lipoplex formulations for gene delivery. Gene Ther 1998; 5 1272-1282.

1997

Barnfield C et al. Characterization of gene expression following intranasal immunization with nucleic acid. Biochem Soc Trans 1997; 25 335S.
Doh SG et al. Spatial-temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA. Gene Ther 1997; 4 648-663.
Doolan DL et al. DNA vaccines for malaria: the past, the present, & the future. Indian J Med Res 1997; 106 109-119.
Duncan JE, Whitsett JA, Horowitz AD. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum Gene Ther 1997; 8 431-438.
Eastman SJ et al. Biophysical characterization of cationic lipid: DNA complexes. Biochim Biophys Acta 1997; 1325 41-62.
El Ouahabi A et al. The role of endosome destabilizing activity in the gene transfer process mediated by cationic lipids. FEBS Lett 1997; 414 187-192.
Fasbender A, Zabner J, Zeiher BG, Welsh MJ. A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia. Gene Ther 1997; 4 1173-1180.
Felgner JH. Separation and quantitation of cationic liposome components by high performance liquid chromatography with evaporative light-scattering detection. Pharm Res 1997; 14 1269-1271.
Felgner PL. Nonviral strategies for gene therapy. Sci Am 1997; 276 102-106.
Felgner PL et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8 511-512.
Gao L et al. Mucosal delivery of nucleic acid elicits both cellular and humoral immunity. Biochem Soc Trans 1997; 25 336S.
Gramzinski RA et al. Malaria DNA vaccines in Aotus monkeys. Vaccine 1997; 15 913-915.
Hedstrom RC et al. The development of a multivalent DNA vaccine for malaria. Springer Semin Immunopathol 1997; 19 147-159.
Hersh EM, Stopeck AT. Advances in the biological therapy and gene therapy of malignant disease. Clin Cancer Res 1997; 3 2623-2629.
Hersh EM, Stopeck AT. Recent advances in the treatment of malignant melanoma with gene therapy. Mol Med 1997; 3 636-651.
Hersh EM et al. Phase II study of intratumoral injection of HLA-B7/beta 2M plasmid DNA-cationic lipid complex (Allovectin-7) therapy for metastatic malignant melanoma (MMM). Cancer Gene Therapy 1997; 4 124.
Hoffman SL et al. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine 1997; 15 842-845.
Hoffman SL et al. Toward clinical trials of DNA vaccines against malaria. Immunol Cell Biol 1997; 75 376-381.
Horton H et al. Gene therapy of ovarian cancer via IL-2 plasmid DNA and cationic lipid. Cancer Gene Therapy 1997; 4 149.
Hsiao M et al. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival. Biochem Biophys Res Commun 1997; 233 359-364.
Klavinskis LS et al. Mucosal immunization with DNA-liposome complexes. Vaccine 1997; 15 818-820.
Kochel T et al. Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice. Vaccine 1997; 15 547-552.
Konopka K, Harrison GS, Felgner PL, Duzgunes N. Cationic liposome-mediated expression of HIV-regulated luciferase and diphtheria toxin a genes in HeLa cells infected with or expressing HIV. Biochim Biophys Acta 1997; 1356 185-197.
Luke CJ, Carner K, Liang X, Barbour AG. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J Infect Dis 1997; 175 91-97.
Marquet M, Horn NA, Meek JA. Characterization of plasmid DNA vectors for use in human gene therapy.1. Biopharm-The Technology & Business Of Biopharmaceuticals 1997; 10 40-45.
Norman JA et al. Development of improved vectors for DNA-based immunization and other gene therapy applications. Vaccine 1997; 15 801-803.
Parker SE, Ducharme S, Norman J, Wheeler CJ. Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum Gene Ther 1997; 8 393-401.
Rodman DM et al. In vivo gene delivery to the pulmonary circulation in rats: transgene distribution and vascular inflammatory response. Am J Respir Cell Mol Biol 1997; 16 640-649.
Rubin J et al. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther 1997; 4 419-425.
Rubin J et al. Phase I/II trial of the IL-2 DNA/DMRIE/DOPE lipid complex as an immunotherapeutic agent by direct gene transfer in patients with advanced melanoma, renal cell carcinoma, and sarcoma. Cancer Gene Therapy 1997; 4 125.
Snyder DS et al. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Biol Blood Marrow Transplant 1997; 3 179-186.
Stopeck AT et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 1997; 15 341-349.
Tanner FC, Carr DP, Nabel GJ, Nabel EG. Transfection of human endothelial cells. Cardiovasc Res 1997; 35 522-528.
Teifel M, Heine LT, Milbredt S, Friedl P. Optimization of transfection of human endothelial cells. Endothelium 1997; 5 21-35.
Waddill W, 3rd et al. Human gene therapy for melanoma: CT-guided interstitial injection. AJR Am J Roentgenol 1997; 169 63-67.
Zuidam NJ, Barenholz Y. Electrostatic parameters of cationic liposomes commonly used for gene delivery as determined by 4-heptadecyl-7-hydroxycoumarin. Biochim Biophys Acta 1997; 1329 211-222.

1996

Bebok Z et al. Efficiency of plasmid delivery and expression after lipid-mediated gene transfer to human cells in vitro. J Pharmacol Exp Ther 1996; 279 1462-1469.
Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis 1996; 173 800-807.
Doolan DL et al. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med 1996; 183 1739-1746.
Felgner PL. Improvements in cationic liposomes for in vivo gene transfer. Hum Gene Ther 1996; 7 1791-1793.
Gardner MJ et al. DNA vaccines against malaria: immunogenicity and protection in a rodent model. J Pharm Sci 1996; 85 1294-1300.
Hartikka J et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7 1205-1217.
Konopka K, Pretzer E, Felgner PL, Duzgunes N. Human immunodeficiency virus type-1 (HIV-1) infection increases the sensitivity of macrophages and THP-1 cells to cytotoxicity by cationic liposomes. Biochim Biophys Acta 1996; 1312 186-196.
Lahijani R et al. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 1996; 7 1971-1980.
Liang X et al. Novel, high expressing and antibiotic-controlled plasmid vectors designed for use in gene therapy. Gene Ther 1996; 3 350-356.
McCarthy M. DNA vaccination: a direct line to the immune system. Lancet 1996; 348 1232.
Nabel GJ et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93 15388-15393.
Oku N et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochim Biophys Acta 1996; 1280 149-154.
Parker SE et al. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo. Cancer Gene Ther 1996; 3 175-185.
Schwarz LA et al. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 1996; 7 731-741.
Stephan DJ et al. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum Gene Ther 1996; 7 1803-1812.
Syrengelas AD, Chen TT, Levy R. DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 1996; 2 1038-1041.
Tripathy SK et al. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector. Proc Natl Acad Sci USA 1996; 93 10876-10880.
Wheeler CJ et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung. Proc Natl Acad Sci USA 1996; 93 11454-11459.
Wheeler CJ et al. Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta 1996; 1280 1-11.
Zhu J et al. A continuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther 1996; 3 472-476.

1995

Fasbender AJ, Zabner J, Welsh MJ. Optimization of cationic lipid-mediated gene transfer to airway epithelia. Am J Physiol 1995; 269 L45-51.
Felgner PL, Zaugg RH, Norman JA. Synthetic recombinant DNA delivery for cancer therapeutics. Cancer Gene Ther 1995; 2 61-65.
Felgner PL et al. Improved cationic lipid formulations for in vivo gene therapy. Ann N Y Acad Sci 1995; 772 126-139. 
Harrison GS et al. Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34+ hematopoietic cells. Biotechniques 1995; 19 816-823. 
Hoffman SL et al. Nucleic acid malaria vaccines. Current status and potential. Ann N Y Acad Sci 1995; 772 88-94. 
Horn NA, Meek JA, Budahazi G, Marquet M. Cancer gene therapy using plasmid DNA: purification of DNA for human clinical trials. Hum Gene Ther 1995; 6 565-573. 
Lew D et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6 553-564. 
Logan JJ et al. Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther 1995; 2 38-49. 
Marquet M, Horn NA, Meek JA. Process Development for the Manufacture of Plasmid DNA Vectors for Use in Gene Therapy. BioPharm 1995; 8 26-37. 
Mor G et al. Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol 1995; 155 2039-2046. 
Norman JA et al. Preclinical pharmacokinetics, manufacturing, and safety studies supporting a multicenter cancer gene therapy trial. Hum Gene Ther 1995; 6 549-550. 
Parker SE et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995; 6 575-590. 
Zabner J et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270 18997-19007.

1994

Abai A, Kuwhara-Rundell A, Margalith M, Morrow J, Parker SE, Rhodes GH. Coinjection of the Genes for Interlukin-2 and Antigen does not Increase Humoral Immune Response. In: Norrby E BF, Chanock RM, Ginsberg HS (ed). Vaccines 94. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1994, pp. 77-81.
Felgner JH et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J Biol Chem 1994; 269 2550-2561.
Nabel GJ et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5 57-77.
Plautz GE et al. Direct gene transfer for the understanding and treatment of human disease. Ann N Y Acad Sci 1994; 716 144-153.
Raz E et al. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91 9519-9523.
Raz E, Carson DA, Rhodes GH, Abai AM, Tsai YJ, Wheeler CJ, Morrow J, Felgner PL, Baird SM. Cationic Lipids Inhibit Intradermal Genetic Vaccination. In: Norrby E BF, Chanock RM, Ginsberg HS (ed). Vaccines 94. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1994, pp. 71-75.
Rhodes GH et al. Characterization of humoral immunity after DNA injection. Dev Biol Stand 1994; 82 229-236.
Schmid S, Rhodes G, Morrow J, Hoffman SL, Kang AS. Nucleic acid vaccines against the preerythrocytic stage of rodent malaria Plasmodium yoelii. Cold Spring Harbor Symposium, October 1994 (abstract).
Sedegah M, Hedstrom R, Hobart P, Hoffman SL. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994; 91 9866-9870.
Sorscher EJ et al. Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trial of safety and efficacy in the nasal airway. Hum Gene Ther 1994; 5 1259-1277.
Vahlsing HL et al. Immunization with plasmid DNA using a pneumatic gun. J Immunol Methods 1994; 175 11-22.
Vogelzang NJ, Lestingi TM, Sudakoff G, Kradjian SA. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum Gene Ther 1994; 5 1357-1370.
Zhou X et al. Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 1994; 12 1510-1514. 

1993

Cohen J. Naked DNA points way to vaccines. Science 1993; 259 1691-1692.
Duzgunes N, Felgner PL. Intracellular delivery of nucleic acids and transcription factors by cationic liposomes. Methods Enzymol 1993; 221 303-306.
Dwarki VJ, Malone RW, Verma IM. Cationic liposome-mediated RNA transfection. Methods Enzymol 1993; 217 644-654.
Felgner PL. Genes in a bottle. Lab Invest 1993; 68 1-3.
Liu M, Ulmer JB, Friedman A, Martinex D, Hawe LA, DeWitt CM, Leander KR, Shi X-P, Montogomery DL, Donnelly JJ, Parker S, Felgner P, Felgner J. Immunization with DNA Encoding a Conserved Internal Viral Protein Results in Protection from Morbidity and Mortality Due to Challenge with Influenza A in Mice. In: Ginsberg HS BF, Chanock RM, Lerner RA (ed). Vaccines 93. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1993, pp. 343-346.
Manthorpe M et al. Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Hum Gene Ther 1993; 4 419-431.
Nabel GJ, Felgner PL. Direct gene transfer for immunotherapy and immunization. Trends Biotechnol 1993; 11 211-215.
Nabel GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90 11307-11311.
Rhodes GH et al. Injection of expression vectors containing viral genes induces cellular, humoral and protective immunity. In: Ginsberg HS (ed). Vaccines 93. Cold Spring Harbor Press: Cold Spring Harbor, NY, 1993, pp. 137-141.
San H et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4 781-788.
Ulmer JB et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259 1745-1749.
Yankauckas MA et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol 1993; 12 771-776.

1992

Jiao S et al. Persistence of plasmid DNA and expression in rat brain cells in vivo. Exp Neurol 1992; 115 400-413.
Kumar R, Gardner MF, Richman DD, Hostetler KY. Equal inhibition of HIV replication by stereoisomers of phosphatidyl-azidothymidine. Lack of stereospecificity of lysosomal phospholipase A1. J Biol Chem 1992; 267 20288-20292.
Nabel EG, Plautz G, Nabel GJ. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci USA 1992; 89 5157-5161.

1991

Felgner PL, Rhodes G. Gene therapeutics. Nature 1991; 349 351-352.
King DH. Fluorinated pyrimidines: a new change for old drugs. Transplant Proc 1991; 23 168-170.

1990

Hostetler KY et al. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J Biol Chem 1990; 265 6112-6117.
Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247 1465-1468.

1989

Duzgunes N, Goldstein JA, Friend DS, Felgner PL. Fusion of liposomes containing a novel cationic lipid, N- [2,3-(dioleyloxy)propyl]-N,N,N-trimethylammonium: induction by multivalent anions and asymmetric fusion with acidic phospholipid vesicles. Biochemistry 1989; 28 9179-9184.
Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989; 337 387-388.
Felgner PL, Holm M, Chan H. Cationic liposome mediated transfection. Proc West Pharmacol Soc 1989; 32 115-121.
Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989; 86 6077-6081.

1987

Felgner PL et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84 7413-7417.






CONNECT WITH US



RSS Feeds 
Email Alerts 
LinkedIn 
Slideshare 
StockTwits 
Twitter 
YouTube




VAXFECTIN®PUBLICATIONS


Published scientific articles on Vaxfectin®



RELATED LINKS

PubMed











About Us

OverviewCorporate GovernanceBoard of Directors

Board Committees

ManagementCareers

Technology

DNA Technology

Poloxamer Delivery System

Vaxfectin® AdjuvantPublications

Products

PipelineASP0113 Therapeutic CMV VaccineCyMVectin™ Prophylactic CMV VaccineVCL-HB01 Therapeutic HSV-2 VaccineVL-2397 AntifungalOther Products

Apex®-IHNDengue VaccineONCEPT®



Clinical Trials

Overview & Active Programs

Investors

OverviewStock InformationNews ReleasesEvents & PresentationsSEC Filings

Contact Us

Contact InfoDirections to VicalCareers









CONNECT WITH US


RSS Feeds Email Alerts LinkedIn Slideshare StockTwits Twitter YouTube 




 © 2017 Vical Inc.
    



Privacy Policy
Terms of Use
Site Map




P. 858 646 1100
10390 Pacific Center Court, San Diego, California 92121
    



        Designed by Mentus



Powered By Q4 Inc. 4.5.0.5


        This link to a non-Vical website is provided as a resource. Vical assumes no responsibility for content not provided by Vical, or for practices or standards of any non-Vical websites.
    











